Page last updated: 2024-08-21

indazoles and axitinib

indazoles has been researched along with axitinib in 414 studies

Research

Studies (414)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	50 (12.08)	29.6817
2010's	350 (84.54)	24.3611
2020's	14 (3.38)	2.80

Authors

Authors	Studies
Collins, JM	1
Freddo, JL; Herbst, RS; Kies, MS; Liu, G; Park, JW; Pithavala, YK; Reich, SD; Rugo, HS; Steinfeldt, HM; Wilding, G	1
Brasch, RC; Fu, YJ; Henry, RG; Hu-Lowe, DD; Hylton, NM; Li, KL; McShane, TM; Pallavicini, MG; Park, JW; Shalinsky, DR; Wilmes, LJ	1
Baffert, F; Hu-Lowe, D; Kuo, CJ; Le, T; McDonald, DM; Sennino, B; Thurston, G	1
Anderson, KD; Davis, RB; Gowen, LC; Hashizume, H; Haskell, A; Joho, S; Kamba, T; Kuo, CJ; Mancuso, MR; McDonald, DM; Norberg, SM; O'Brien, SM; Sennino, B; Springer, ML; Tam, BY; Thurston, G	1
Bellamy, WT; Beran, M; Bycott, P; Estrov, Z; Giles, FJ; List, AF; O'Brien, SM; Pithavala, Y; Ravandi, F; Reich, SD; Steinfeldt, H; Verstovsek, S; Yee, KW	1
Rini, BI	3
Hu-Lowe, DD; McDonald, DM; Nakahara, T; Norberg, SM; Shalinsky, DR	1
Kanetake, H; Koga, S	1
Arap, W; Chanthery, YH; Kasman, IM; McDonald, DM; Ozawa, MG; Pasqualini, R; Varner, AS; Yao, VJ	1
Chew, K; Fong, K; Jaeger, E; Rini, BI; Sein, N; Simko, J; Small, EJ; Waldman, FM; Weinberg, V	1
Eto, M; Naito, S	1
Mancuso, A; Sternberg, CN	1
Brooks, P; Davis, R; Freimark, B; Hu-Lowe, DD; Inai, T; Mancuso, MR; McDonald, DM; Nakahara, T; Norberg, SM; O'Brien, S; Sennino, B; Shalinsky, DR; Yao, VJ	1
George, DJ	1
Brasch, RC; Fleming, LM; Gibbs, J; Henry, RG; Hu-Lowe, D; Hylton, NM; Li, KL; Lu, Y; McShane, TM; Pallavicini, MG; Park, JW; Partridge, SC; Shalinsky, DR; Wang, D; Wilmes, LJ	1
Baz, RC; Bukowski, RM; Choueiri, TK; Elson, P; Garcia, JA; Golshayan, AR; Khasawneh, M; Rini, BI; Usman, S; Wood, L	1
Kibble, A	1
Armand, JP; Mir, O; Ropert, S	1
Fenton, BM; Paoni, SF	2
Bolte, O; Bukowski, RM; Bycott, P; Freddo, J; Hudes, GR; Kim, S; Liau, KF; Michaelson, MD; Motzer, RJ; Rini, BI; Rixe, O; Trask, PC; Wilding, G	1
Linehan, WM	1
Ma, J; Waxman, DJ	2
Hutson, TE; Rini, BI; Sonpavde, G	1
Sherman, SI	2
Philip, PA	1
Bajetta, E; Barone, C; Bycott, P; Chodkiewicz, C; Kim, S; Létourneau, R; Liau, K; Maurel, J; Pithavala, Y; Ricart, AD; Rixe, O; Spano, JP; Trask, P; Wasan, H; Wong, R	1
Choueiri, TK	1
Bycott, P; Cohen, EE; Cohen, RB; Forastiere, AA; Kane, MA; Kies, MS; Kim, S; Liau, KF; Rosen, LS; Shalinsky, DR; Sherman, E; Tortorici, M; Vokes, EE; Worden, FP	1
Bushmakin, AG; Bycott, P; Cappelleri, JC; Kim, S; Liau, K; Trask, PC	1
Bhalla, IP; Bukowski, RM; Choueiri, TK; Elson, P; Ganapathi, R; Golshayan, AR; Jaeger, E; Rini, BI; Sein, N; Sercia, L; Simko, J; Small, EJ; Vaziri, SA; Waldman, FM; Weinberg, V; Wood, L; Zhou, M	1
Bukowski, RM; Vakkalanka, BK	1
Döme, B; Magyar, M	1
Amundson, K; Bender, SL; Chen, JH; Grazzini, ML; Hallin, ME; Hu-Lowe, DD; Kania, RS; McTigue, MA; Murray, BW; O'Connor, P; Rewolinski, DA; Shalinsky, DR; Wickman, GR; Wu, EY; Yamazaki, S; Zou, HY	1
Alexandre, I; Billemont, B; Meric, JB; Richard, S; Rixe, O	1
Bastien, L; Culine, S; de la Taille, A; Ledbai, S; Patard, JJ; Paule, B	1
Hu-Lowe, DD; Kuhnert, F; Kuo, CJ; Mancuso, MR; McDonald, DM; Sennino, B; Tabruyn, SP	1
Bergqvist, S; Cobbs, M; Diehl, W; Kania, RS; Marrone, T; McTigue, MA; Murray, BW; Quenzer, T; Ryan, K; Solowiej, J	1
Bycott, P; Kim, S; Larson, T; Liau, K; Limentani, S; Olszanski, AJ; Ou, SH; Sandler, A; Schiller, JH; Vokes, E; von Pawel, J	1
Garrett, M; Hee, B; Klamerus, KJ; Kuruganti, U; Ni, G; Pithavala, YK; Toh, M; Tortorici, M	1
Dutcher, JP; Hudes, G; Kim, S; Rini, BI; Rosbrook, B; Stadler, WM; Tarazi, J; Trask, PC; Wilding, G; Wood, L	1
Cella, D	1
Barone, C; Chodkiewicz, C; Kim, S; Maurel, J; Ricart, AD; Rosbrook, B; Spano, JP; Springett, GM; Wasan, HS; Wong, R	1
Kelly, RJ; Rixe, O	2
Beijnen, JH; Iusuf, D; Schellens, JH; Schinkel, AH; Sparidans, RW	1
Abhyankar, V; Burgess, RE; Chen, Y; Infante, J; Kim, S; Robles, RL; Sharma, S; Tarazi, J; Tortorici, M; Trowbridge, RC	1
Bayer, M; Berdel, WE; Kessler, T; Liersch, R; Mesters, RM; Schwöppe, C	1
Moretti, S; Puxeddu, E; Romagnoli, S; Voce, P	1
Hashimoto, J; Itoh, K; Minami, H; Mukai, H; Mukohara, T; Nagai, S; Nakajima, H; Umeyama, Y	1
Greten, TF; Manns, MP; Plentz, RR	1
Abramov, YA; Campeta, AM; Chekal, BP; Henson, MJ; Horspool, KR; Meenan, PA; Shi, B; Singer, RA	1
Alvey, CW; Fuentes, E; Green, M; Hee, B; Labadie, RR; Marbury, T; Ni, G; Pithavala, YK; Rahavendran, SV; Toh, M; Tortorici, MA	1
Campeta, AM; Chekal, BP; Samas, B; Seadeek, C	1
Bourredjem, A; Daudigeos-Dubus, E; Farace, F; Geoerger, B; Monnet, Y; Opolon, P; Rössler, J; Vassal, G	1
Garrett, M; Hee, B; Klamerus, KJ; Mount, J; Pithavala, YK; Rahavendran, SV; Sarapa, N; Selaru, P; Tong, W	1
Goldstein, R; Larkin, J; Pickering, L	1
Guo, F; Khamly, K; Michael, M; Olszanski, AJ; Pierce, KJ; Vlahovic, G	1
Beijnen, JH; Iusuf, D; Poller, B; Schinkel, AH; Sparidans, RW; Wagenaar, E	1
Chayahara, N; Fujiwara, Y; Kiyota, N; Minami, H; Mukohara, T; Suzuki, A; Umeyama, Y	1
Bennouna, J; Bycott, P; Funakoshi, A; Furuse, J; Ioka, T; Kim, S; Kindler, HL; Létourneau, R; Ohkawa, S; Okusaka, T; Park, YS; Ricart, AD; Richel, DJ; Springett, GM; Trask, PC; Van Cutsem, E; Wasan, HS	1
Alì, G; Bocci, G; Canu, B; Danesi, R; Del Tacca, M; Di Desidero, T; Di Paolo, A; Fioravanti, A; Fontanini, G; Orlandi, P	1
Cheng, G; Likar, MD; Mahajan, N; Zhang, Z	1
Blute, T; Chen, CS; Ma, J; Waxman, DJ	1
Alves, MM; de Groot, JW; Hofstra, RM; Links, TP; Osinga, J; Plukker, JT; Verbeek, HH	1
Bair, AH; Cohen, EE; Fruehauf, JP; Kim, S; Letrent, KJ; Olszanski, AJ; Ricart, AD; Rini, BI; Rixe, O; Rosbrook, B; Schiller, JH; Tarazi, JC	1
Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES	1
Bair, AH; Bycott, P; Chan, S; Joy, AA; Kim, S; Liau, KF; Lluch, A; Rosbrook, B; Rugo, HS; Soulieres, D; Stopeck, AT; Verma, S	1
Schneider, BP; Sledge, GW	1
Kim, S; Moore, MJ; Pithavala, YK; Ricart, AD; Rixe, O; Spano, JP	1
Escudier, B; Gore, M	1
Pal, SK; Vogelzang, NJ	1
Akaza, H; Fujimoto, H; Imai, K; Kanayama, HO; Naito, S; Nakazawa, H; Ozono, S; Shinohara, N; Tomita, Y; Uemura, H; Umeyama, Y	1
Brown, CK; Fruehauf, J; Kim, S; Liau, KF; Lutzky, J; McDermott, D; Meric, JB; Niethammer, AG; Rixe, O; Rosbrook, B; Shalinsky, DR	1
Chen, Y; Hu, P; Jiang, J; Lu, L; Ni, G; Pithavala, YK; Tortorici, MA; Zhang, J	1
Ho, TH; Jonasch, E	1
Bex, A; Haanen, J	1
Castellano, D; Cella, D; Chen, C; Escudier, B; Gorbunova, VA; Gore, ME; Hutson, TE; Kaprin, A; Kim, S; Lim, HY; Michaelson, MD; Motzer, RJ; Negrier, S; Ou, YC; Rini, BI; Rosbrook, B; Rusakov, IG; Szczylik, C; Tarazi, J; Tomczak, P; Uemura, H	1
Eibl, K; Haritoglou, C; Kampik, A; Kernt, B; Kernt, M; Liegl, RG; Thiele, S; Ulbig, MW	1
Brennan, M; Chen, Y; Liu, YC; Pithavala, Y; Tortorici, M; Williams, JA	1
Goozner, M	1
Doloff, JC; Waxman, DJ	1
B Cohen, R; Olszanski, AJ; Patson, B	1
Bruyere, F; Carmier, D; Combe, P; D'Arcier, BF; Linassier, C; Narciso, B	1
Döme, B; Török, S	1
Brand-Saberi, B; Foehring, D; Theiss, C	1
Bose, A; Lowe, DB; Rao, A; Storkus, WJ	1
Chen, SP; Chen, XG; Cheng, C; Fu, LW; Liang, YJ; Liu, Z; Mi, YJ; To, KK; Wang, F; Wu, XP	1
Hayward, R; Marais, R; Martin, MJ; Viros, A	1
Powles, T	1
Fujioka, T; Iwasaki, K; Obara, W	1
Daimon, M; Kaino, W; Kameda, W; Karasawa, S; Kato, T; Oizumi, T; Susa, S; Takase, K; Tomita, Y; Wada, K	1
Chen, Y; Garrett, M; Hee, B; Klamerus, KJ; LaBadie, RR; Mount, J; Ni, G; Pithavala, YK; Selaru, P; Toh, M; Tortorici, MA	1
He, B; Xie, F; Zhao, J; Zhao, T	1
Carmichael, C; Josephson, DY; Lau, C; Pal, SK	1
Beijnen, JH; Schellens, JH; van Geel, RM	1
Abramov, YA; Klamt, A; Loschen, C	1
Arriola, E; Cohen, RB; De Castro Carpeño, J; Herbst, RS; Kim, S; Kozloff, MF; Krzakowski, M; Martin, LP; Olszanski, AJ; Rado, TA; Rosbrook, B; Samuel, TA; Tarazi, J; Tortorici, M	1
Chen, Y; Cohen, RB; Herbst, RS; Kim, S; Kozloff, MF; Martin, LP; Olszanski, AJ; Rado, T; Rosbrook, B; Samuel, TA; Starr, A; Tarazi, J; Tortorici, M	1
Cserepes T, M; Döme, B; Rényi-Vámos, F; Török, S	1
Cho, WK; Choi, HS; Kang, S; Kim, SH; Park, KC; Roh, CR; Roh, YJ; Yang, KJ	1
Abramov, YA; Lupyan, D; Sherman, W	1
Bowles, DW; Flaig, TW; Jimeno, A; Kessler, ER; Lam, ET	1
Matsunaga, H; Matsushita, A; Nakamura, H; Ohba, K; Oki, Y; Ozono, S; Sasaki, S; Takayama, T	1
Lin, CC; Pu, YS; Wang, JY	1
McKeage, K; Yang, LP	1
Manley, E; Waxman, DJ	1
Adhikari, LJ; Ames, MM; Gilbert, JA; Halfdanarson, TR; Lloyd, RV; Muders, MH	1
Cappelleri, JC; Chen, C; Foley, G; Healey, PJ; Kroes, M; Larkin, J; Mitchell, S; Paine, A; Tumur, I	1
Chen, CS; Chen, WM; Cheng, CL; Chiu, KY; Ho, HC; Li, JR; Ou, YC; Su, CK; Wang, SS; Yang, CK; Yang, CR	1
Hussar, DA	1
Alasker, A; Bianchi, M; Hanna, N; Hansen, J; Ismail, S; Karakiewicz, PI; Meskawi, M; Perrotte, P; Sun, M; Tian, Z	1
Mittal, K; Rini, B	1
Brooks, MM; Cammarata, PR; Neelam, S	1
Fischer, A; Ho, AL; Lacouture, ME; Wu, S	1
Andrews, L; Fishman, M; Gorbunova, V; Jonasch, E; Larkin, J; Negrier, S; Olivier, K; Pyle, L; Staehler, M; Wood, L	1
Cortesi, E; Iacovelli, R; Mezi, S; Naso, G; Palazzo, A; Pellegrino, D; Trenta, P	1
Bloom, J; Bycott, P; de La Motte Rouge, T; Grünwald, V; Harzstark, AL; Ingrosso, A; Kim, S; Liu, G; Michaelson, MD; Motzer, RJ; Rini, BI; Tortorici, MA	1
King, JW; Lee, SM	1
Eibl, K; Haritoglou, C; Kampik, A; Kernt, M; König, S; Langer, J; Liegl, RG; Siedlecki, J; Thiele, S	1
Dutcher, JP; Garrett, M; Kim, S; Motzer, RJ; Pithavala, YK; Poland, B; Rini, BI; Rixe, O; Stadler, WM; Tarazi, J; Wilding, G	1
Boeck, S; Haas, M; Heinemann, V; Holdenrieder, S; Kern, C; Nagel, D; Stieber, P; Wittwer, C	1
Bhattacharyya, H; Cella, D; Chen, C; Escudier, B; Kim, S; Motzer, R; Rini, B; Rosbrook, B; Tarazi, J	1
Bex, A	1
Chen, C; Escudier, B; Gore, ME; Hariharan, S; Hutson, TE; Kim, S; Michaelson, MD; Motzer, RJ; Negrier, S; Oudard, S; Rini, BI; Rosbrook, B; Tarazi, J; Tomczak, P	1
Cartwright, TH; Cescon, TP; Cohn, AL; Edenfield, WJ; Hamm, JT; Infante, JR; Kim, S; Malik, IA; McGee, PJ; Rado, TA; Reid, TR; Richards, DA; Rosbrook, B; Tarazi, J	1
He, AN; Qi, WX; Shen, Z; Yao, Y	1
Fahldieck, C; Kalich, J; Lichtenfels, R; Riemann, D; Schulz, K; Seliger, B; Stehle, F	1
Akaza, H; Chen, C; Kanayama, H; Kim, S; Naito, S; Ozono, S; Shinohara, N; Tarazi, J; Tomita, Y; Tsukamoto, T; Ueda, T; Uemura, H	1
Waxman, DJ; Zhang, K	1
Kai, F; Nagata, M; Ozono, S; Sugiyama, T; Takayama, T	1
Chen, Y; Garrett, M; Hee, B; Klamerus, KJ; Pithavala, YK; Tortorici, MA	1
Clouser-Roche, A; Fenner, K; Freiwald, S; Lee, CA; Reyner, EL; Sevidal, S; Smith, BJ; Ullah, M; West, MA	1
Amantea, MA; Brennan, M; Garrett, M; Hee, B; Pithavala, YK; Poland, B	1
Agarwal, KL; Bakris, GL; Bhatta, SS; Cohen, EE; Karrison, T; Maitland, ML; Ratain, MJ; Seiwert, TY; Sit, L; Vokes, EE; Wroblewski, KE	1
Bejot, R; Bhakoo, KK; Goggi, JL; Moonshi, SS	1
Groppi, VE; McEwen, DP; O'Clair, B; Wolfe, A	1
Adomako-Ankomah, A; Ettensohn, CA	1
Broom, RJ; Dranitsaris, G; Schmitz, S	1
Cai, P; Chen, W; Fang, X; Gao, Z; Gu, Y; Shu, Y; Sun, Y; Tao, F; Xu, Q; Yuan, H; Zhang, X	1
Albiges, L; Ammari, S; Benmoussa, L; Escudier, B; Levy, A	1
Buti, S; Porta, C	1
Andrews, GI; Arranz, JA; Bair, AH; Fishman, MN; Grünwald, V; Jonasch, E; Kim, S; Melichar, B; Pavlov, D; Pithavala, YK; Rini, BI; Ueda, T	1
Barone, C; Bendell, JC; Bloom, J; Kim, JG; Kim, S; Pastorelli, D; Pericay, C; Ricart, AD; Rosbrook, B; Sobrero, AF; Swieboda-Sadlej, A; Tarazi, J; Tournigand, C; Wainberg, ZA	1
Al-Shukri, S; Bair, AH; Chen, C; Hutson, TE; Kim, S; Lesovoy, V; Lipatov, ON; Rosbrook, B; Stus, VP; Vogelzang, NJ	1
Larkin, J; Yousaf, N	1
Brown, NJ; Reed, MW; Staton, CA; Woll, PJ; Young, RJ	1
Hashimoto, Y; Hatakeyama, S; Imai, A; Koie, T; Ohyama, C; Okamoto, A; Yamamoto, H; Yoneyama, T	1
Akaza, H; Fukuyama, T	1
Bycott, P; Chen, C; Chmielowska, E; de Besi, P; Havel, L; Ingrosso, A; Kim, S; Olszanski, AJ; Popat, S; Sawrycki, P; Schiller, JH; Swieboda-Sadlej, A; Twelves, C; Williams, JA	1
Calogero, A; Ciccone, AM; De Falco, E; Ibrahim, M; Menna, C; Pacini, L; Petrozza, V; Puca, R; Rendina, EA; Ruggieri, P; Scafetta, G	1
Khenifer, S; Pasquet, F; Pavic, M; Péron, J; Potier, V; Rassat, R; Vitry, T	1
Balasubramaniam, S; Edgerly, M; Fojo, T; Nguyen, D; O'Sullivan, C; Pittaluga, S; Velarde, M; Venkatesan, AM; Wilkerson, J; Yang, SX	1
Bendell, JC; Burris, HA; Hoh, CK; Infante, JR; Kim, S; Reid, TR; Rosbrook, B; Tarazi, J	1
Evans, CE; Grover, SP; Humphries, J; Lyons, OT; Modarai, B; Patel, AP; Patel, AS; Saha, P; Smith, A; Waltham, M	1
Edwards, RJ; Gu, R; Hibbs, DE; Murray, M; Ong, JA	1
Behera, R; Mensa-Wilmot, K; Thomas, SM	1
Ahrar, K; Devine, CE; Karam, JA; Lozano, M; Maity, T; Tamboli, P; Tannir, NM; Urbauer, DL; Wood, CG	1
Bachier, CR; Bucay, M; Esquenazi, Y; Ovadia, D	1
Funahashi, Y; Gotoh, M; Inoue, S; Kato, M; Maeda, M; Sassa, N	1
Pesch, L	1
Bellmunt, J; Calvo, E; Grünwald, V	1
Arruda, LS; Baum, M; Cisar, L; Kim, S; Motzer, RJ; Quinn, DI; Rini, BI; Roberts, WG; Rosbrook, B; Tarazi, J; Wood, LS	1
Bu, HZ; Dalvie, DK; Deese, AJ; Hee, B; Kang, P; Klamerus, KJ; Pithavala, Y; Pool, WF; Smith, BJ; Wu, EY	1
Choueiri, TK; Heng, DY; Lin, X; McKay, RR; Perkins, JJ; Simantov, R	1
Galsky, MD; Leiter, A	1
Bracarda, S; Castellano, D; Procopio, G; Schmidinger, M; Sepúlveda, JM; Sisani, M; Verzoni, E	1
Miyajima, A; Mizuno, R; Oya, M	1
Heinzlmeir, S; Helm, D; Ku, X; Kuster, B; Médard, G	1
Avril, N; Hagemann, T; Hudson, CD; Mather, SJ	1
Figlin, RA; Posadas, EM	1
Furukawa, H; Furuse, J; Ojima, H; Shibata, T; Shimizu, H; Takahashi, H	1
Wada, Y	1
Belani, CP; Bondarenko, IM; Bycott, P; Ingrosso, A; Kim, S; Niethammer, AG; Novello, S; Poltoratskiy, A; Scagliotti, GV; Tang, J; Yamamoto, N	1
Afonso, R; Angeles, C; Campos, JM; García-Alfonso, P; Grande, E; Jorge, M; Martínez, V; Montagut, C; Polo, E; Reina, JJ	1
Cheng, J; Fuks, Z; Haimovitz-Friedman, A; Kolesnick, RN; Powell, SN; Rao, SS; Thompson, C	1
Gao, J; Ge, S; He, Q; Li, Y; Peng, Z; Shen, L; Wang, T	1
Cisar, L; Clark, JI; Escudier, B; Hariharan, S; Hutson, TE; Kannourakis, G; Kim, S; Lim, HY; Michaelson, MD; Motzer, RJ; Porfiri, E; Rini, BI; Rosbrook, B; Staehler, M; Tarazi, J; Zalewski, P	1
Agate, L; Boucher, A; Bycott, P; Chen, C; Cohen, EE; Ingrosso, A; Jarzab, B; Kane, MA; Kim, S; Licitra, L; Locati, LD; Ou, SH; Pithavala, YK; Qin, S; Wirth, LJ	1
Schmidinger, M	1
Berkers, J; Beuselinck, B; De Wever, L; Dumez, H; Joniau, S; Lerut, E; Oyen, R; Paridaens, R; Schöffski, P; Strijbos, M; Van Poppel, H; Wolter, P	1
Arruda, LS; Borst, DL; MacLean, E; Morgado, JE; Pithavala, YK	1
Conrads, TP; Haines, DC; Hilton, MB; Kalen, J; Logsdon, D; Morris, H; Patel, NL; Seaman, S; St Croix, B; Stevens, J; Swing, DA; Veenstra, TD; Xu, L; Zudaire, E	1
Abdel-Rahman, O; Fouad, M	1
Chiang, HI; Fan, YK; Ju, JC; Kastelic, JP; Kere, M; Liao, JW; Lo, NW; Siriboon, C	1
Cai, P; Gu, Y; Li, Q; Sun, Y; Wang, W; Xu, Q; Yuan, H	1
Bagcchi, S	1
Diakou, A; Feidas, H; Kantzoura, V; Kouam, MK; Theodoropoulos, G; Theodoropoulou, H	1
Egawa, S; Endo, K; Hatano, T; Ishii, G; Kimura, T; Seki, K; Yamada, H	1
Günaydın, ZY; Gürel, E; Karaoğlanoğlu, M; Kırış, T	1
Lu, L; Martuza, RL; Rabkin, SD; Saha, D; Wakimoto, H	1
Bao, J; Li, J; Li, X; Luo, K; Wu, C; Zhang, W; Zhou, N	1
Bourlon, MT; Kessler, ER	1
Carver, BS; Doran, MG; Evans, MJ; Sawyers, CL; Spratt, DE; Ulmert, D; Wongvipat, J	1
Badalamenti, G; Baldi, GG; Casali, PG; Cominetti, D; Dagrada, GP; Dei Tos, AP; Festinese, F; Fumagalli, E; Grignani, G; Gronchi, A; Morosi, C; Negri, T; Pennacchioli, E; Pilotti, S; Provenzano, S; Spagnuolo, RD; Stacchiotti, S; Tortoreto, M; Toss, A; Zaffaroni, N	1
Affolter, T; Christensen, J; Eisele, K; Eswaraka, J; Feng, Z; Giddabasappa, A; Han, G; Lalwani, K; Li, G	1
Akaza, H; Eto, M; Fujii, Y; Kamei, Y; Kanayama, H; Naito, S; Ozono, S; Shinohara, N; Tomita, Y; Uemura, H; Umeyama, Y	1
Chernova, M; Gao, L; Jia, W; Mihm, MC; Nadora, DM; Nelson, JS; Phan, S; Preciado, SM; Sun, V; Tan, W; Wang, G	1
Nishiyama, T; Niwa, N; Ozu, C; Saito, S; Yagi, Y	1
Bycott, P; Cohen, EE; Ingrosso, A; Kim, S; Pithavala, YK; Tortorici, M	1
Cohen, EE; Fruehauf, JP; Garrett, M; Kim, S; Pithavala, YK; Ruiz-Garcia, A; Tortorici, MA	1
Bair, AH; Chen, Y; Mugundu, GM; Pithavala, YK; Rini, BI	1
Ebihara, S; Ebihara, T; Gui, P; Ichinose, M; Kikuchi, T; Kobayashi, M; Nagatomi, R; Nihei, M; Niu, K; Nukiwa, T; Okazaki, T; Tamai, T; Yamaya, M	1
Albiges, L; Boyle, H; Ederhy, S; Escudier, B; Gravis, G; Hartl, D; Izzedine, H; Robert, C; Scotté, F	1
Adelaiye, R; Barrera, G; Ciamporcero, E; Ku, S; Miles, KM; Pili, R; Pizzimenti, S; Ramakrishnan, S; Sennino, B; Shen, L	1
Casciano, R; Chua, A; Culver, K; Garrison, LP; Gorritz, M; Liu, Z; Pal, S; Perrin, A; Sherman, S; Wang, X	1
Fujisawa, M; Harada, K; Imai, S; Miyake, H; Miyazaki, A	1
Ishii, K; Mori, A; Morita, A; Nakahara, T; Sakamoto, K; Ushikubo, H	1
Cass, CE; Damaraju, VL; Kuzma, M; Mowles, D; Sawyer, MB	1
Han, Y; Li, P; Song, K; Xie, Z; Xu, X; Zhang, L; Zhao, Y; Zhou, L; Zhou, P	1
Aspinall, A; Bathe, OF; Burak, KW; Chen, E; Dhani, N; Horgan, AM; Kim, TK; Knox, JJ; Le, LW; Lo, G; McNamara, MG; Rogalla, P; Sinaei, M	1
Acharya, G; Hua, X; Isenhart, LC; Marcano, DC; Pflugfelder, SC; Shin, CS; Yuan, X	1
Houk, BE; Pithavala, YK; Ruiz-Garcia, A; Sarapa, N; Toh, M; Tortorici, MA	1
Hamada, A; Inoue, T; Kamba, T; Kobayashi, T; Matsui, Y; Negoro, H; Ogawa, O; Sugino, Y; Terada, N; Yamasaki, T; Yoshimura, K	1
Forsyth, PA; Kenchappa, RS; Kurz, EU; Lun, X; McFadden, G; McKenzie, BA; Narendran, A; Pisklakova, A; Zemp, FJ	1
Bergh, J; Borregaard, J; Dalhus, M; Damkier, P; Ersbøll, J; Hofland, K; Mickisch, G; Pieters, R; Pignatti, F; Salmonson, T; Skibeli, V; Slot, KB; Sylvester, R; Thoresen, H; Tzogani, K; Westgaard, I	1
Carcangiu, ML; Cohen, EE; Greco, A; Joseph, L; Khattri, A; Licitra, L; Lingen, MW; Locati, LD; Nagilla, M; Pelosi, G; Reddy, P; Schechter, RB; Seiwert, TY; Watson, S	1
Boku, N; Bycott, P; Fujii, Y; Furuse, J; Ioka, T; Kamei, Y; Namazu, K; Ohkawa, S; Okusaka, T; Sawaki, A; Takahashi, S; Umeyama, Y	1
Chen, Y; Garrett, M; LaBadie, RR; Pithavala, YK; Suzuki, A; Tortorici, MA; Umeyama, Y	1
Liu, J; Zhang, B; Zhang, X; Zhou, T	1
Chen, J; Cronin, CN; Johnson, E; Kallioniemi, O; Kontro, M; McTigue, M; Murray, BW; Pemovska, T; Porkka, K; Repasky, GA; Wells, P; Wennerberg, K	1
Agarwal, N; Beard, C; Bhayani, S; Bolger, GB; Chang, SS; Choueiri, TK; Costello, BA; Derweesh, IH; Dwyer, M; Gupta, S; Hancock, SL; Jonasch, E; Kim, JJ; Kumar, R; Kuzel, TM; Lam, ET; Lau, C; Levine, EG; Lin, DW; Michaelson, MD; Motzer, RJ; Olencki, T; Pili, R; Plimack, ER; Rampersaud, EN; Redman, BG; Ryan, CJ; Sheinfeld, J; Shuch, B; Sircar, K; Somer, B; Wilder, RB	1
Bair, AH; Chen, Y; Fishman, MN; Grünwald, V; Melichar, B; Oya, M; Pithavala, YK; Rini, BI	1
Mikudina, B; Stevens, A; Sutcliffe, F; Umeweni, N	1
Berndsen, RH; Bonvin, D; Dyson, PJ; Griffioen, AW; Nowak-Sliwinska, P; Scherrer, E; Weiss, A; Wong, TJ	1
English, PA; Escudier, B; Huang, X; Kim, S; Loomis, AK; Motzer, RJ; Rini, BI; Rosbrook, B; Tarazi, J; Williams, JA	1
Dintsios, CM; Rasch, A	1
Qin, S; Zhang, S	1
Algazi, AP; Bastian, BC; Behr, S; Cha, E; Chong, K; Coakley, F; Cortez, B; Daud, AI; Hwang, J; Liu, S; McCalmont, T; Ortiz-Urda, SM; Pampaloni, MH; Quiroz, A	1
Hashimoto, Y; Hatakeyama, S; Imai, A; Koie, T; Mori, K; Ohyama, C; Tobisawa, Y; Yamamoto, H; Yoneyama, T	1
Albiges, L; Carton, E; Escudier, B; Gizzi, M	1
Bondarenko, IM; Bycott, P; Cebotaru, CL; Ingrosso, A; Kim, S	1
Petrou, P	2
Bruce, JY; Carmichael, LL; Eickhoff, JC; Heideman, JL; Jeraj, R; Kolesar, JM; Liu, G; Perlman, SB; Scully, PC	1
Blanco, T; Bock, F; Cursiefen, C; Dana, R; Hos, D; Lee, HS; Mathew, R; Reyes, NJ; Saban, DR	1
Abel, EJ; Allaf, ME; Bex, A; Devine, CE; Fellman, BM; Karam, JA; Lane, BR; Thompson, RH; Urbauer, DL; Wood, CG	1
Rixe, O; Zakharia, K; Zakharia, Y	1
Brossart, P; Daecke, SN; Flores, C; Heine, A; Held, SA; Kotthoff, P; Kurts, C; Riethausen, K	1
Iguchi, T; Kato, M; Nakatani, T; Ninomiya, N; Tamada, S; Yamasaki, T	1
Costa, HC; Feio, RN; Moura, MR	1
Ohyashiki, K; Okabe, S; Sakuta, J; Tanaka, Y; Tauchi, T	1
Honda, A; Kawano, H; Kogure, Y; Kume, H; Kurokawa, M; Nannya, Y; Shinoda, Y; Toya, T; Ushiku, T; Yamashita, H; Yoshimi, A	1
Fukuhara, H; Kato, T; Kawazoe, H; Nishida, H; Sakurai, T; Shibasaki, T; Tomita, Y; Yamagishi, A	1
Askerova, Z; DeAnnuntis, LL; Escudier, B; Hariharan, S; Motzer, RJ; Rini, BI; Roberts, WG; Rosbrook, B; Tarazi, J	1
Covell, LL; Ganti, AK	1
Tomita, Y	1
Greenberg, A; Matta, SK; Singh, A	1
Fujisawa, M; Harada, K; Imai, S; Miyake, H	1
Collet, G; Dulak, J; Jozkowicz, A; Kieda, C; Kloska, D; Szade, A; Szade, K; Zukowska, M	1
Bhattacharyya, H; Casey, M; Chakrabarti, D; Chan, SL; Chen, C; Kang, YK; Kim, RD; Kudo, M; Lee, TY; Lim, HY; Obi, S; Park, JW; Qin, S; Valota, O; Williams, JA; Yau, T	1
Canavese, M; Crisanti, A; Dottorini, T	1
Chen, Y; Dutcher, JP; Garrett, M; Motzer, RJ; Pithavala, YK; Rini, BI; Rixe, O; Stadler, WM; Tarazi, J; Wilding, G	1
Iizuka, N; Ishii, K; Mori, A; Nakahara, T; Sakamoto, K; Ushikubo, H	1
Berndsen, RH; Ding, X; Dyson, PJ; Griffioen, AW; Ho, CM; Nowak-Sliwinska, P; van den Bergh, H; Weiss, A	1
Fujisawa, M; Imai, S; Miyake, H	1
Abramova, E; Atochina-Vasserman, EN; Ersumo, NT; Gow, AJ; Guo, CJ; James, ML; Krymskaya, VP; Liu, AY; Rue, R	1
Agarwal, N; Carmichael, C; Deng, J; Figlin, RA; Jones, JO; Lau, C; Liu, X; Pal, SK; Pinnamaneni, M; Ruel, N; Twardowski, P; Vuong, W; Yu, H; Zhang, W	1
Belile, E; Bradford, C; Carey, T; Chepeha, DB; Dobrosotskaya, I; Eisbruch, A; Malloy, K; McKean, E; McLean, S; Moyer, J; Prince, M; Sacco, AG; Shuman, A; Spector, M; Swiecicki, PL; Wolf, GT; Worden, FP; Zhao, L	1
Amantini, C; Cardinali, C; Morelli, MB; Nabissi, M; Santoni, A; Santoni, G; Santoni, M; Soriani, A	1
Burge, F; Sundar, S	1
Keating, GM	1
Ishii, K; Mori, A; Nakahara, T; Nakano, A; Sakamoto, K; Ushikubo, H	1
Choi, JN; Galan, A; Odell, ID; Shi, VJ	1
Chehab, F; Gunthorpe, M; Holmes, JP; Lasater, EA; Massi, ES; Politi, J; Sali, A; Shah, NP; Smith, CC; Stecula, A; Tan, SK	1
Bauman, JN; Freiwald, S; Goosen, TC; Jiang, Y; Kang, P; Lin, J; Neul, D; Smith, BJ; Tseng, E; Walker, GS; Zientek, MA	1
Crawford, K; Dusing, M; Frischer, JS; Knod, JL	1
Albiges, L; Choueiri, TK; De Velasco, G; Fay, AP; Heng, DY; Kaymakcalan, MD; Kollmannsberger, CK; Kroeger, N; Lee, JL; McKay, RR; North, SA; Rha, SY; Smoragiewicz, M; Wells, JC; Xie, W	1
Grünwald, V; Ivanyi, P	1
Izumi, K; Konaka, H; Mizokami, A; Namiki, M; Yaegashi, H	1
Deininger, MW; Druker, BJ; Eide, CA; O'Hare, T; Pomicter, AD; Savage, SL; Vellore, NA; Yan, D; Zabriskie, MS	1
Fujisawa, M; Miyake, H; Miyazaki, A	1
Cartenì, G; Vitale, MG	1
Gillessen, S; Hader, C; Rothermundt, C	1
Jonasch, E; Li, N; Liu, Z; Pal, SK; Perez, JR; Reichmann, WM; Signorovitch, JE; Vogelzang, NJ	1
Adomi, S; Minami, T; Nose, K; Nozawa, M; Ohzeki, T; Saito, Y; Shimizu, N; Sugimoto, K; Uemura, H; Yoshimura, K	1
Czarnecka, AM; Kornakiewicz, A; Solarek, W; Szczylik, C	1
Balar, AV; Bangalore, S; Kang, SK; Ohmann, EL; Volodarskiy, A	1
Daido, Y; Kitamura, Y; Nishimoto, K; Shinchi, Y; Takao, M; Tokonabe, S; Yoshii, H	1
Jonasch, E; Li, N; Liu, Z; Pal, SK; Perez, JR; Reichmann, WM; Signorovitch, JE; Vogelzang, NJ; Yang, C	1
Griswold, J; Parekh, H; Rini, B	1
Alexandre, J; Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Bretagne, M; Cabanes, L; Cessot, A; Chahwakilian, A; Coriat, R; Goldwasser, F; Huillard, O; Orvoen, G; Thomas-Schoemann, A; Tlemsani, C	1
Baas, P; Buikhuisen, WA; Griffioen, AW; Korse, CM; Scharpfenecker, M; van Tinteren, H	1
Diaz, J; Pandha, H; Sapunar, F; Sehgal, M; Takyar, S	1
Brummer, T; Dengjel, J; Ellermann, J; Gretzmeier, C; Halbach, S; Hu, Z; Wöhrle, FU	1
Eswaraka, J; Giddabasappa, A; Gukasyan, HJ; Klamerus, K; Lalwani, K; Mosyak, L; Norberg, R; Paterson, D; Rittenhouse, K; Schachar, RA	1
Bouttens, F; D'Haene, N; Du Four, S; Duerinck, J; Everaert, H; Le Mercier, M; Michotte, A; Neyns, B; Salmon, I; Van Binst, AM; Vandervorst, F; Verschaeve, V	1
Chittoria, N; Dreicer, R; Elson, P; Garcia, JA; Haddad, H; Jonasch, E; Rini, BI; Tannir, NM; Wood, LS	1
Al Zahrani, H; Burns, P; Hudson, J; Jang, HJ; Kandel, S; Khalili, K; Kim, TK; Knox, J; Lo, GM; McNamara, MG; Menezes, R; Rogalla, P	1
Atreya, CE; Bergsland, EK; Cives, M; Coppola, D; Hwang, J; Kelley, RK; Morse, B; Nickerson, M; Strosberg, JR; Valone, T; Venook, A; Weber, T	1
Aerts, JL; Benteyn, D; De Keersmaecker, B; Du Four, S; Duerinck, J; Maenhout, SK; Neyns, B; Thielemans, K	1
Keck, B; Lieb, V; Lüdecke, G; Sikic, D	1
Allen, E; Hanahan, D; Li, L; Miéville, P; Peng, MW; Saghafinia, S; Warren, CM	1
Huang, Y; Li, L; Sun, W; Xu, X; Zhou, Z	1
Dainichi, T; Hirakawa, S; Honda, T; Kabashima, K; Kitoh, A; Miyachi, Y; Nakajima, S; Nakashima, C; Nonomura, Y; Otsuka, A; Wong, LS; Yamamoto, Y	1
Choi, HG; Choi, JY; Jeong, JH; Kim, J; Kim, JO; Kim, JR; Kim, SY; Ku, SK; Ramasamy, T; Yong, CS; Youn, YS	1
Bernhard, JC; Daste, A; François, L; Gross-Goupil, M; Quivy, A; Ravaud, A	1
Spector, M; Swiecicki, PL; Worden, FP	1
Cisar, L; Eremina, D; MacLean, E; Mehle, K; Quigley, JM	1
Andrews, GI; Bair, AH; Fishman, MN; Grünwald, V; Jonasch, E; Melichar, B; Oya, M; Rini, BI; Rosbrook, B; Tomita, Y; Ueda, T; Uemura, H	1
Grünwald, V; Kalanovic, D; Lin, X; Simantov, R	1
Alimzhanov, M; Alsop, DC; Atkins, MB; Bhasin, MK; Bhatt, RS; Callea, M; Khanna, P; Kumar, R; Mier, JW; Pearsall, RS; Signoretti, S; Solban, N; Song, J; Wang, X	1
Bedke, J; Gauler, T; Grünwald, V; Hegele, A; Herrmann, E; Hinz, S; Janssen, J; Miller, K; Schmitz, S; Schostak, M; Tesch, H; Zastrow, S	1
Chai, Y; Chen, Y; Gao, J; Guo, H; Li, S; Liu, J; Lv, P; Pan, Y; Yan, X; Zhou, Y	1
Abe, H; Arai, K; Fukuda, T; Kamai, T; Masuda, A; Nukui, A; Yoshida, K	1
Fujisaki, A; Komatsubara, M; Kurokawa, S; Morita, T; Yamazaki, M	1
Alias, Z; Feroz, SR; Izzudin, MM; Kabir, MZ; Mohamad, SB; Tayyab, S; Tee, WV	1
Fujisawa, M; Harada, K; Miyake, H; Ozono, S	1
Bruno, R; Chanu, P; Chen, Y; Claret, L; Mercier, F; Milligan, PA; Rosbrook, B; Yazdi, P; Zheng, J	1
Fujisawa, M; Harada, KI; Miyake, H; Ozono, S	1
Blicher, P; Brokstad, KA; Dalhus, B; Gharbi, N; Kalland, KH; Ke, X; Lin, B; Olsen, JR; Qu, Y; Yuan, X; Zhang, W; Øyan, AM	1
Eisen, T; Escudier, B; Grünwald, V; Larkin, J; McDermott, D; Oldenburg, J; Porta, C; Putora, PM; Rini, B; Rothermundt, C; Schmidinger, M; Sternberg, CN; von Rappard, J	1
Haumann, R; Poot, AJ; Schuit, RC; Slobbe, P; van Dongen, GA; Windhorst, AD	1
Al-Shukri, S; Andrews, GI; Bair, AH; Hutson, TE; Lipatov, ON; Rosbrook, B; Shparyk, Y; Stus, VP; Vogelzang, NJ	1
Bieche, I; Bousquet, G; Bryan, BA; de Gramont, A; Dos Santos, C; Faivre, S; Gapihan, G; Janin, A; Lopez, A; Martinet, M; Mitchell, DC; Neuzillet, C; Raymond, E; Riveiro, ME; Serova, M; Tijeras-Raballand, A	1
Antonescu, CR; Baxi, SS; Chandramohan, R; Cullen, GD; Dogan, S; Dunn, L; Fury, MG; Haque, S; Ho, AL; Katabi, N; Morris, LG; Ni, A; Pfister, DG; Sherman, EJ; Sima, CS	1
Asai, M; Gotoh, M; Iwai, A; Kato, H; Miyazaki, M; Noda, Y; Sassa, N; Takeuchi, M; Yamada, K	1
Maltezou, M; Miaris, N; Papaxoinis, G; Samantas, E; Visvikis, A	1
Campanario, R; Juárez, A; Saiz, R; Soto, M	1
Allman, K; Beach, J; Elson, P; Garcia, JA; Gilligan, T; Martin, A; Ornstein, MC; Rini, BI; Wood, L	1
Calvo, E; Escudier, B; Grünwald, V; Heng, DY; Schmidinger, M	1
Arai, Y; Asano, T; Isono, M; Ito, K; Koga, A; Masunaga, A; Shinchi, Y; Tachi, K	1
Amantea, MA; Chen, Y; Garrett, M; Ingrosso, A; Mould, DR; Pithavala, YK; Taylor, T	1
Burton, B; Primeaux, B; Shuey, S	1
Bruce, JY; Carmichael, L; Eickhoff, J; Jeraj, R; Kolesar, J; Liu, G; Perlman, S; Scarpelli, M	1
Hatano, K; Ishizuya, Y; Kakimoto, KI; Nakai, Y; Nakayama, M; Nishimura, K; Okusa, T	1
Bawa, O; Bosq, J; Daudigeos-Dubus, E; Geoerger, B; Le Dret, L; Opolon, P; Vassal, G; Vievard, A; Villa, I	1
Amantini, C; Bernardini, G; Cardinali, C; Morelli, MB; Nabissi, M; Santoni, A; Santoni, G; Santoni, M	1
Begemann, G; Draut, H; Rehm, T; Schobert, R	1
Albiges, L; Bensalah, K; Bex, A; Canfield, SE; Dabestani, S; Fernández-Pello, S; Giles, RH; Hofmann, F; Hora, M; Kuczyk, MA; Lam, TB; Ljungberg, B; Marconi, L; Merseburger, AS; Powles, T; Staehler, M; Tahbaz, R; Volpe, A	1
Bandara, NA; Bates, CD; Hoylman, EK; Low, PS; Lu, Y	1
Campitiello, M; Eid, N; Hennequin, L; Longo, R; Plastino, F; Quétin, P; Wendel, C	1
Ding, K; Ding, S; Fei, J; Gao, X; Han, W; Hui, X; Kristiansen, K; Li, K; Li, P; Lin, X; Liu, P; Liu, X; Madsen, L; Mao, L; Nie, B; Nie, T; Tang, X; Wang, Y; Wu, D; Xu, A; Xu, Y; Yuan, R; Zhou, Z	1
Afriansyah, A; Hamid, AR; Mochtar, CA; Umbas, R	1
Eibl-Lindner, K; Liegl, R; Priglinger, C; Priglinger, S; Siedlecki, J; Wertheimer, C; Wolf, A	1
Abe, K; Iwata, T; Kakoki, K; Miyata, Y; Mochizuki, Y; Nagayasu, T; Obatake, M; Sakai, H	1
Iwamura, M; Koguchi, D; Minamida, S; Shimura, S; Taoka, Y	1
Ghate, SR; Li, N; Liu, Z; Pal, SK; Perez, JR; Signorovitch, JE; Vogelzang, NJ; Zichlin, ML	1
Bair, AH; Fujii, Y; Fukasawa, S; Habuchi, T; Kamei, Y; Oya, M; Rini, BI; Shinohara, N; Tomita, Y; Uemura, H; Umeyama, Y	1
Albiges, L; Ficarra, V; Heng, DY; Hsieh, JJ; Larkin, J; Purdue, MP; Schmidinger, M; Signoretti, S; Swanton, C	1
Boerboom, D; Carmeliet, P; Cui, P; Deisseroth, K; Feng, Y; Hsueh, AJ; Hsueh, B; Lu, X; Möller Billig, F; Tomer, R; Zarnescu Yanez, L	1
Bair, AH; Cisar, L; Fishman, MN; Gruenwald, V; Hariharan, S; Hutson, TE; Jonasch, E; Michaelson, MD; Rini, BI; Rosbrook, B; Tarazi, J; Tomita, Y	1
Amantea, MA; Friberg, LE; Karlsson, MO; Schindler, E	1
Barnes, K; Bendell, JC; Blachly, R; Blakely, L; Earwood, C; Joseph, M; Kuzur, M; Lane, CM; Mainwaring, M; Reddy, C; Shipley, D	1
Bouchet, S; Calcagno, F; Devillard, N; Mouillet, G; Orillard, E; Royer, B; Thiery-Vuillemin, A	1
Akula, S; Duyster, J; Kamasani, S; Kancha, RK; Manga, V; Sivan, SK; Vudem, DR	1
Cisar, L; Hutson, TE; Jiao, X; MacLean, EA; Wilson, T	1
Albiges, L; Bacciarelo, G; Brard, C; Escudier, B; Fizazi, K; Guida, A; Lassau, N; Le Teuff, G; Loriot, Y; Massard, C; Matias, M	1
Boyle, H; Brachet, PE; Coquan, E; Dugué, AE; Escudier, B; Helissey, C; Johnson, AC; Joly, F; Laguerre, B; Matias, M; Molinier, A; Mourey, L	1
Morimoto-Kamata, R; Yui, S	1
Cook, G; Goh, V; Kelly-Morland, C; Mallett, S; Montana, G; Nathan, P; Rudman, S	1
Chan, AWH; Chan, SL; Chong, CCN; Hui, EP; Koh, J; Lai, PBS; Li, L; Mo, F; Mok, TSK; Yeo, W; Yu, SCH	1
Choueiri, TK; Kaymakcalan, MD; Lalani, AA; Lin, X; McKay, RR; Simantov, R	1
Furuse, J; Kasuga, A; Kawai, K; Kobayashi, T; Nagashima, F; Naruge, D; Okano, N	1
Adrián, SG; Aller, J; Astorga, BG; Bohn, U; Cajal, TRY; Capdevila, J; Cillán, E; Duran-Poveda, M; Grande, E; Grau, JJ; Llopis, CZ; López-Alfonso, A; Manzano, JL; Martínez, JM; Matos, I; Palacios, N; Porras, I; Reig, Ò; Reina, JJ; Trigo, JM	1
Akaza, H; Shibasaki, Y; Umeyama, Y	1
Gu, J; Li, J	1
Durand-Zaleski, I; Fleury, L; Maroun, R; Maunoury, F; Nachbaur, G; Vanhille, JL	1
Fujita, N; Hamano, I; Hashimoto, Y; Hatakeyama, S; Hosogoe, S; Iwamura, H; Koie, T; Kusaka, A; Ohyama, C; Tanaka, T; Tanaka, Y; Tobisawa, Y; Yamamoto, H; Yoneyama, T	1
Chen, Q; Wang, J; Wang, M; Zhong, C	1
Asselineau, J; Aziza, R; Baud, J; Bikfalvi, A; Chauzit, E; Chevreau, C; Cornelis, F; Daste, A; Delord, JP; Digue, L; Doussau, A; Gimbert, A; Gomez-Roca, C; Molimard, M; Pedenon-Périchout, D; Picat, MQ; Quemener, C; Ravaud, A; Sitta, R	1
Gandhi, S; George, S; Jain, RK	1
Albiges, L; Derosa, L; Escudier, B; Fizazi, K; Guida, A; Loriot, Y; Massard, C	1
Kwok, J; Patel, V; Sproat, C; Tanna, N	1
Kikuchi, E; Mikami, S; Mizuno, R; Oya, M; Shinojima, T; Takamatsu, K	1
Alexandre, J; Bellesoeur, A; Carton, E; Goldwasser, F; Huillard, O	1
Ariad, S; Douvdevani, A; Dresler, H; Keizman, D; Mermershtain, W; Neulander, EZ; Riff, R; Rouvinov, K; Shani-Shrem, N	1
De Meyer, GRY; Martinet, W; Van der Veken, B	1
Bista, M; Collins, T; Gray, K; Hardy, C; Harmer, AR; Mettetal, JT; Skinner, M; Wang, H	1
Danesi, R; Jones, R; McDermott, R; Négrier, S; Pyle, L; Rini, B; Schmidinger, M	1
García-Alemán, J; Mancha-Doblas, I; Molina-Vega, M; Sebastián-Ochoa, A; Tinahones-Madueño, F; Trigo-Pérez, JM	1
Albiol-Chiva, J; Esteve-Romero, J; Peris-Vicente, J	1
Liu, D; Ren, H; Sun, X; Wang, J; Wang, M; Xiao, G; Xu, C; Zhang, B; Zhang, J	1
Casati, A; Craveiro, RB; Dilloo, D; Ehrhardt, M; Olschewski, M; Pietsch, T; Schönberger, S; Velz, J	1
Buchi, M; D'Amico, L; Kashyap, AS; Läubli, H; Müller, P; Zippelius, A	1
Dai, Q; Dong, M; Liang, J; Peng, S; Sun, Q; Wei, N	1
Duchesneau, E; Ghate, S; McDonald, E; Messali, A; Perez, JR; Swallow, E	1
Kato, Y; Miyata, T; Nakahara, J; Oya, M; Yazawa, S	1
Kumari, A; Silakari, O; Singh, RK	1
Bodnar, L; Chrom, P; Czarnecka, AM; Kawecki, M; Stec, R; Szczylik, C	1
Huang, Y; Xu, XL	1
Bourn, J; Cekanova, M	1
Fujita, M; Kuroda, T; Mukai, M; Nakai, Y; Nishimura, K; Oka, T; Shioyama, W; Takada, M; Yasui, T	1
Chikui, K; Hirano, T; Igawa, T; Matsuo, M; Nakiri, M; Nishihara, K; Ogasawara, N; Suekane, S; Ueda, K; Uemura, K	1
Albiges, L; Barthélémy, P; Bouleftour, W; Chevreau, C; Culine, S; Espenel, S; Fizazi, K; Gravis, G; Guillot, A; Houede, N; Joly, C; Mahammedi, H; Meriaux, E; Negrier, S; Oriol, M; Pouessel, D; Roubaud, G; Tartas, S; Tinquaut, F; Vassal, C	1
Hamilton, BJ; Stan, RV; Tse, D	1
Borchiellini, D	1
Albiges, L; Auclin, E; Auvray, M; Barthelemy, P; Bono, P; De Velasco, G; Escudier, B; Gravis, G; Gross-Goupil, M; Kellokumpu-Lehtinen, P; Mouillet, G; Mourey, L; Powles, T; Priou, F; Rolland, F; Vano, YA	1
Cozar Olmo, JM; Exposito Ruiz, M; Hernández Hernández, C; Varilla-Varilla, C; Vázquez Alonso, F	1
Donskov, F; Fristrup, N	1
Crucitta, S; Danesi, R; Del Re, M; Fogli, S; Gianfilippo, G; Porta, C; Rini, BI; Schmidinger, M	1
Albersen, M; Baldewijns, M; Beuselinck, B; Bourgain, C; Debruyne, PR; Haaker, L; Laenen, A; Laguerre, B; Lerut, E; Oudard, S; Renders, I; Rioux-Leclercq, N; Roussel, E; Tryssesoone, L; Van den Bulck, H; Verbiest, A; Wynendaele, W	1
Feng, C; Li, Y; Shen, Y; Wen, H; Zhu, Z	1
Eisen, T; Fife, K; Gordon, J; Hawkins, R; Hurst, M; Matakidou, A; Naicker, N; Nolasco, S; Wang, M	1
Barzaghi, P; Perego, G; Petrelli, F; Vavassori, I	1
Chun, FKH; Deuker, M; Karakiewicz, PI	1
Bex, A; Hofmann, F; Hwang, EC; Lam, TB; Ljungberg, B; Marconi, LS; Yuan, Y	1
Hayashi, T; Ijiri, Y; Imano, H; Kato, R	1
Eto, M; Hara, T; Ito, YM; Kashiwagi, A; Kawasaki, Y; Kitamura, H; Kojima, T; Minami, K; Miyauchi, Y; Morizane, S; Morooka, D; Murai, S; Murakami, M; Nakagomi, H; Nakai, Y; Nishiyama, H; Ohba, K; Osawa, T; Ozawa, M; Sazuka, T; Shimazui, T; Shinohara, N; Sugimoto, M; Takeuchi, A; Tomida, R; Ueda, K; Uemura, M; Yamamoto, Y; Yasumoto, H	1
Armstrong, AJ; Brown, LC; Campbell, MT; Corn, P; Economides, M; Gao, J; Garmezy, B; George, DJ; Gupta, RT; Harrison, MR; Jonasch, E; Kao, C; Kinsey, EN; Laccetti, AL; Msaouel, P; Shah, A; Tannir, N; Venkatesan, A; Xiao, L; Zhang, T; Zurita-Saavedra, A	1
Fujisawa, M; Hara, T; Harada, K; Suzuki, K; Terakawa, T	1
Chung, HS; Kim, SH; Kwon, TG; Lee, JL; Park, SH; Shim, BY; Shin, SJ	1
Jiang, H; Jin, C; Liao, J; Mo, J; Wang, L; Xiang, S	1
Anai, S; Eto, M; Hara, H; Hara, T; Ito, YM; Kimura, T; Kitamura, H; Kojima, T; Minami, K; Mitsuzuka, K; Miyauchi, Y; Morizane, S; Murai, S; Nakagomi, H; Nakai, Y; Nishiyama, H; Ohba, K; Osawa, T; Ozawa, M; Shiina, H; Shimazui, T; Shindo, T; Shinohara, N; Takahashi, A; Takeuchi, A; Tamura, K; Ueda, K; Uemura, M; Yokomizo, A; Yoshimura, K	1

Reviews

86 review(s) available for indazoles and axitinib

Article	Year
SU11248 and AG013736: current data and future trials in renal cell carcinoma. Clinical genitourinary cancer, 2005, Volume: 4, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sunitinib	2005
[Progress in therapeutic strategy for renal cell carcinoma]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Catheter Ablation; Combined Modality Therapy; Female; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Minimally Invasive Surgical Procedures; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib	2006
VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices. Current oncology reports, 2006, Volume: 8, Issue:2 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; ErbB Receptors; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein	2006
Molecular targeting therapy for renal cell carcinoma. International journal of clinical oncology, 2006, Volume: 11, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib	2006
New treatment approaches in metastatic renal cell carcinoma. Current opinion in urology, 2006, Volume: 16, Issue:5 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Erlotinib Hydrochloride; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2006
Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Jan-15, Volume: 13, Issue:2 Pt 2 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Cytokines; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Phenotype; Platelet-Derived Growth Factor; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein	2007
[Oral drugs inhibiting the VEGF pathway]. Bulletin du cancer, 2007, Volume: 94 Spec No Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Asthenia; Axitinib; Benzenesulfonates; Humans; Hypertension; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Proteinuria; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A	2007
Axitinib for renal cell carcinoma. Expert opinion on investigational drugs, 2008, Volume: 17, Issue:5 Topics: Angiogenesis Inhibitors; Animals; Axitinib; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Drug Evaluation; Humans; Imidazoles; Indazoles; Kidney Neoplasms	2008
Early clinical studies of novel therapies for thyroid cancers. Endocrinology and metabolism clinics of North America, 2008, Volume: 37, Issue:2 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Carcinoma; Clinical Trials as Topic; Drug Delivery Systems; Gefitinib; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Sorafenib; Thyroid Neoplasms	2008
Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. Current opinion in investigational drugs (London, England : 2000), 2008, Volume: 9, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Axitinib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Contraindications; Humans; Imidazoles; Indazoles; Neoplasms; Patents as Topic; Randomized Controlled Trials as Topic; Structure-Activity Relationship	2008
Novel drugs for renal cell carcinoma. Expert opinion on investigational drugs, 2008, Volume: 17, Issue:10 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2008
[Tumor vasculature as a therapeutic target in non-small cell lung cancer]. Magyar onkologia, 2008, Volume: 52, Issue:3 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Imidazoles; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Xanthones	2008
Targeted therapies in metastatic renal cancer in 2009. BJU international, 2009, Volume: 103, Issue:10 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factors	2009
Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. Cancer, 2009, May-15, Volume: 115, Issue:10 Suppl Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A	2009
Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes. Cancer treatment reviews, 2009, Volume: 35, Issue:8 Topics: Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Everolimus; Health Status; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Patient Satisfaction; Phenylurea Compounds; Pyridines; Pyrroles; Quality of Life; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome	2009
Tyrosine kinase inhibitors and the thyroid. Best practice & research. Clinical endocrinology & metabolism, 2009, Volume: 23, Issue:6 Topics: Axitinib; Benzenesulfonates; Clinical Trials as Topic; Gefitinib; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Pharmaceutical Preparations; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins B-raf; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thyroid Gland; Thyroid Neoplasms	2009
Compounds in clinical Phase III and beyond. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2010, Volume: 180 Topics: Angiogenesis Inhibitors; Axitinib; Benzenesulfonates; Clinical Trials, Phase III as Topic; Endostatins; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A	2010
Axitinib (AG-013736). Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2010, Volume: 184 Topics: Angiogenesis Inhibitors; Animals; Axitinib; Biological Availability; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Imidazoles; Indazoles; Neoplasms; Pancreatic Neoplasms; Thyroid Neoplasms	2010
Targeted molecular therapies in thyroid carcinoma. Arquivos brasileiros de endocrinologia e metabologia, 2009, Volume: 53, Issue:9 Topics: Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Medullary; Carcinoma, Papillary; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thyroid Neoplasms	2009
Molecular therapy of pancreatic cancer. Minerva endocrinologica, 2010, Volume: 35, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Capecitabine; Carcinoma, Pancreatic Ductal; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Neoplasm Invasiveness; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phthalazines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A	2010
Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies? Expert review of anticancer therapy, 2010, Volume: 10, Issue:10 Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Neoplasms; Protein Kinase Inhibitors	2010
Novel molecular targeted therapies for refractory thyroid cancer. Head & neck, 2012, Volume: 34, Issue:5 Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat	2012
Axitinib for the management of metastatic renal cell carcinoma. Drugs in R&D, 2011, Volume: 11, Issue:2 Topics: Angiogenesis Inhibitors; Animals; Axitinib; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Imidazoles; Indazoles	2011
Axitinib in the treatment of metastatic renal cell carcinoma. Future oncology (London, England), 2011, Volume: 7, Issue:11 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Receptors, Vascular Endothelial Growth Factor	2011
Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics. European journal of clinical pharmacology, 2012, Volume: 68, Issue:5 Topics: Angiogenesis Inhibitors; Axitinib; Biological Transport; Biotransformation; Clinical Trials, Phase I as Topic; Cytochrome P-450 Enzyme System; Humans; Imidazoles; Indazoles; Isoenzymes; Organic Anion Transporters; Polymorphism, Genetic; Receptors, Vascular Endothelial Growth Factor	2012
Pharmacokinetic evaluation of axitinib. Expert opinion on drug metabolism & toxicology, 2012, Volume: 8, Issue:2 Topics: Animals; Axitinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Pancreatic Neoplasms; Protein Kinase Inhibitors; Thyroid Neoplasms	2012
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors]. Magyar onkologia, 2012, Volume: 56, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Axitinib; Benzenesulfonates; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib	2012
Comprehensive overview of axitinib development in solid malignancies: focus on metastatic renal cell carcinoma. Clinical advances in hematology & oncology : H&O, 2012, Volume: 10, Issue:5 Topics: Animals; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Neoplasm Metastasis; Neoplasms; Protein Kinase Inhibitors	2012
Concise drug review: pazopanib and axitinib. The oncologist, 2012, Volume: 17, Issue:8 Topics: Angiogenesis Inhibitors; Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Meta-Analysis as Topic; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; United States; United States Food and Drug Administration	2012
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects]. Magyar onkologia, 2012, Volume: 56, Issue:3 Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colorectal Neoplasms; Digestive System; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Imidazoles; Indazoles; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays	2012
Axitinib, a new therapeutic option in renal cell carcinoma. Drugs of today (Barcelona, Spain : 1998), 2012, Volume: 48, Issue:10 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Mas	2012
Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis. Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Bayes Theorem; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyrimidines; Randomized Controlled Trials as Topic; Sorafenib; Sulfonamides; Treatment Outcome; Young Adult	2013
Kidney cancer in 2012: new frontiers in kidney cancer research. Nature reviews. Urology, 2013, Volume: 10, Issue:2 Topics: Animals; Axitinib; Biomedical Research; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Humans; Imidazoles; Immunotherapy; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors	2013
The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Investigational new drugs, 2013, Volume: 31, Issue:3 Topics: Axitinib; Hand-Foot Syndrome; Humans; Imidazoles; Incidence; Indazoles; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Risk	2013
Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment. American journal of clinical oncology, 2014, Volume: 37, Issue:6 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Failure; Vascular Endothelial Growth Factor Receptor-2	2014
Axitinib for the treatment of advanced non-small-cell lung cancer. Expert opinion on investigational drugs, 2013, Volume: 22, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Axitinib; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Humans; Imidazoles; Indazoles; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Survival Rate	2013
Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis. British journal of clinical pharmacology, 2013, Volume: 76, Issue:3 Topics: Antineoplastic Agents; Axitinib; Clinical Trials as Topic; Humans; Hypertension; Imidazoles; Incidence; Indazoles; Molecular Targeted Therapy; Neoplasms; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Risk	2013
Clinical pharmacology of axitinib. Clinical pharmacokinetics, 2013, Volume: 52, Issue:9 Topics: Axitinib; Drug Interactions; Humans; Imidazoles; Indazoles; Intestinal Absorption; Neoplasms; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor	2013
Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy. Journal of cancer research and clinical oncology, 2013, Volume: 139, Issue:11 Topics: Antineoplastic Agents; Axitinib; Bayes Theorem; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides	2013
Axitinib for the treatment of advanced renal cell carcinoma. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:2 Topics: Animals; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Survival Rate	2014
Association between takotsubo cardiomyopathy and axitinib: case report and review of the literature. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Jan-01, Volume: 33, Issue:1 Topics: Aged; Axitinib; Carcinoma, Renal Cell; Diagnosis, Differential; Female; Humans; Imidazoles; Indazoles; Liver Neoplasms; Protein Kinase Inhibitors; Takotsubo Cardiomyopathy; Treatment Outcome	2015
Holistic pediatric veterinary medicine. The Veterinary clinics of North America. Small animal practice, 2014, Volume: 44, Issue:2 Topics: Animals; Axitinib; Cats; Complementary Therapies; Dogs; Imidazoles; Indazoles; Veterinary Medicine	2014
Controversies in renal cell carcinoma: treatment choice after progression on vascular endothelial growth factor-targeted therapy. European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:7 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Everolimus; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quality of Life; Sirolimus; Vascular Endothelial Growth Factor A	2014
Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies. Expert opinion on drug safety, 2014, Volume: 13, Issue:4 Topics: Axitinib; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors	2014
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status. Angiogenesis, 2014, Volume: 17, Issue:4 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Genes, ras; Humans; Imidazoles; Indazoles; Indoles; Irinotecan; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A	2014
Improving outcomes in metastatic clear cell renal cell carcinoma by sequencing therapy. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2014 Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Metastasis; Patient Selection; Sirolimus; Treatment Outcome	2014
Common questions regarding clinical use of axitinib in advanced renal cell carcinoma. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2014, Jul-01, Volume: 71, Issue:13 Topics: Animals; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Pharmaceutical Solutions; Protein Kinase Inhibitors	2014
Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis. Critical reviews in oncology/hematology, 2014, Volume: 92, Issue:3 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Cardiovascular Diseases; Humans; Imidazoles; Incidence; Indazoles; Indoles; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Risk; Sunitinib	2014
Pharmacokinetics of single-agent axitinib across multiple solid tumor types. Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Area Under Curve; Axitinib; Biological Availability; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Female; Humans; Imidazoles; Indazoles; Male; Middle Aged; Models, Biological; Neoplasms; Nonlinear Dynamics; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Sex Factors; Tissue Distribution; Young Adult	2014
[Axitinib in metastatic renal carcinomas: update of knowledge about side effects]. Bulletin du cancer, 2014, Volume: 101, Issue:10 Topics: Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors	2014
The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for The oncologist, 2015, Volume: 20, Issue:2 Topics: Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Drug Approval; Europe; Humans; Imidazoles; Indazoles; Indoles; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3	2015
Axitinib plasma pharmacokinetics and ethnic differences. Investigational new drugs, 2015, Volume: 33, Issue:2 Topics: Area Under Curve; Asian People; Axitinib; China; Clinical Trials as Topic; Disease-Free Survival; Half-Life; Humans; Imidazoles; Indazoles; Japan; Metabolic Clearance Rate; Neoplasms; Protein Kinase Inhibitors; Vascular Endothelial Growth Factors; White People	2015
Clinical observation of liver cancer patients treated with axitinib and cabozantinib after failed sorafenib treatment: a case report and literature review. Cancer biology & therapy, 2015, Volume: 16, Issue:2 Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Hepatocellular; Fatal Outcome; Humans; Imidazoles; Indazoles; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Retreatment; Sorafenib; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome	2015
[Subgroups in the early benefit assessment of pharmaceuticals: a methodical review]. Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen, 2015, Volume: 109, Issue:1 Topics: Adenosine; Anilides; Axitinib; Drug Approval; Effect Modifier, Epidemiologic; Fingolimod Hydrochloride; Germany; Humans; Imidazoles; Indazoles; National Health Programs; Pyridines; Risk Assessment; Sitagliptin Phosphate; Sofosbuvir; Ticagrelor	2015
Axitinib in metastatic renal cell carcinoma. Expert review of anticancer therapy, 2015, Volume: 15, Issue:5 Topics: Algorithms; Axitinib; Carcinoma, Renal Cell; Disease Progression; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Metastasis; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor	2015
Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma. Expert opinion on drug discovery, 2015, Volume: 10, Issue:8 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor	2015
Treatment of advanced thyroid cancer: role of molecularly targeted therapies. Targeted oncology, 2015, Volume: 10, Issue:3 Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Neuroendocrine; DNA Mutational Analysis; Drug Approval; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Molecular Targeted Therapy; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Piperidines; Proto-Oncogene Proteins c-ret; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Thyroid Neoplasms; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A	2015
Treatment strategies for advanced renal cell carcinoma: A new paradigm for surgical treatment. International journal of urology : official journal of the Japanese Urological Association, 2016, Volume: 23, Issue:1 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Metastasectomy; Molecular Targeted Therapy; Neoadjuvant Therapy; Pyrroles; Sunitinib	2016
Axitinib: a review in advanced renal cell carcinoma. Drugs, 2015, Volume: 75, Issue:16 Topics: Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Imidazoles; Indazoles; Vascular Endothelial Growth Factor Receptor-1	2015
[Systemic Treatment of Metastatic Renal Cell Cancer--Back to the Future?]. Aktuelle Urologie, 2015, Volume: 46, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Disease Progression; Everolimus; Humans; Imidazoles; Immunotherapy; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis	2015
Clinical management of metastatic kidney cancer: the role of new molecular drugs. Future oncology (London, England), 2016, Volume: 12, Issue:1 Topics: Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2016
Efficacy and Safety of Selective Vascular Endothelial Growth Factor Receptor Inhibitors Compared with Sorafenib for Metastatic Renal Cell Carcinoma: a Meta-analysis of Randomised Controlled Trials. Clinical oncology (Royal College of Radiologists (Great Britain)), 2016, Volume: 28, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzimidazoles; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Quinolines; Quinolones; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate; Vascular Endothelial Growth Factor A	2016
Axitinib for the treatment of metastatic renal cell carcinoma. Future oncology (London, England), 2016, Volume: 12, Issue:3 Topics: Animals; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Humans; Hypertension; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy	2016
[Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management]. Bulletin du cancer, 2016, Volume: 103, Issue:3 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Fatigue; Humans; Imidazoles; Indazoles; Indoles; Kidney; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib	2016
First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials. Anti-cancer drugs, 2016, Volume: 27, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Quality of Life; Quinazolines; Quinolines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2016
[Side effect management of tyrosine kinase inhibitors in urology : Fatigue and hypothyroidism]. Der Urologe. Ausg. A, 2016, Volume: 55, Issue:5 Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Enzyme Inhibitors; Fatigue; Humans; Hypothyroidism; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quality of Life; Sorafenib; Sulfonamides; Sunitinib	2016
Efficacy of Rechallenge of Metastatic Renal Cell Carcinoma Patient With Sunitinib After Prior Resistance to Axitinib: Case Report and Review of the Literature. Clinical genitourinary cancer, 2016, Volume: 14, Issue:5 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Sunitinib	2016
Axitinib in the Treatment of Head and Neck Malignancies. Current clinical pharmacology, 2016, Volume: 11, Issue:2 Topics: Axitinib; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Imidazoles; Indazoles; Molecular Targeted Therapy; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Squamous Cell Carcinoma of Head and Neck; Survival; Thyroid Neoplasms	2016
Systemic therapy in metastatic renal cell carcinoma. World journal of urology, 2017, Volume: 35, Issue:2 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Decision Trees; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Nivolumab; Phenylurea Compounds; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2017
Posterior Reversible Encephalopathy Syndrome With Concurrent Nephrotic Syndrome in a Patient Treated With Pazopanib for Metastatic Renal Cell Carcinoma: Case Report and Review of the Literature. Clinical genitourinary cancer, 2017, Volume: 15, Issue:1 Topics: Axitinib; Carcinoma, Renal Cell; Everolimus; Fatal Outcome; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Magnetic Resonance Imaging; Middle Aged; Nephrotic Syndrome; Posterior Leukoencephalopathy Syndrome; Pyrimidines; Sulfonamides	2017
Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. Cancer treatment reviews, 2016, Volume: 50 Topics: Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; DNA-Binding Proteins; Everolimus; Gene Expression Regulation, Neoplastic; Histone-Lysine N-Methyltransferase; Humans; Imidazoles; Immunologic Factors; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; MicroRNAs; Molecular Targeted Therapy; Mutation; Niacinamide; Nivolumab; Nuclear Proteins; Phenylurea Compounds; Precision Medicine; Prognosis; Pyridines; Pyrimidines; Pyrroles; Quinolines; Receptors, CCR4; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Transcription Factors; Tumor Suppressor Proteins; Ubiquitin Thiolesterase; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein	2016
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma. European urology, 2017, Volume: 71, Issue:3 Topics: Anilides; Antineoplastic Agents; Axitinib; Benzimidazoles; Bevacizumab; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Quinolines; Quinolones; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2017
Targeted Therapy for Metastatic Renal Cell Carcinoma. Acta medica Indonesiana, 2016, Volume: 48, Issue:4 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Immunologic Factors; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2016
Long-term Treatment With Sequential Molecular Targeted Therapy for Xp11.2 Translocation Renal Cell Carcinoma: A Case Report and Review of the Literature. Clinical genitourinary cancer, 2017, Volume: 15, Issue:3 Topics: Adult; Age of Onset; Antineoplastic Agents; Axitinib; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Catheter Ablation; Child; Combined Modality Therapy; Everolimus; Fatal Outcome; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Oncogene Fusion; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Translocation, Genetic; Young Adult	2017
Renal cell carcinoma. Nature reviews. Disease primers, 2017, Mar-09, Volume: 3 Topics: Axitinib; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Kidney; Kidney Diseases; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Quality of Life; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A	2017
Axitinib in metastatic renal cell carcinoma: beyond the second-line setting. Future oncology (London, England), 2017, Volume: 13, Issue:21 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Clinical Trials as Topic; Combined Modality Therapy; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Retreatment; Treatment Outcome	2017
Fatigue associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis. International journal of clinical oncology, 2017, Volume: 22, Issue:5 Topics: Anilides; Axitinib; Fatigue; Humans; Imidazoles; Indazoles; Neoplasms; Odds Ratio; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Receptors, Vascular Endothelial Growth Factor	2017
Second-line systemic therapy in metastatic renal-cell carcinoma: A review. Urologic oncology, 2017, Volume: 35, Issue:11 Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Sorafenib	2017
Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy. Drug design, development and therapy, 2017, Volume: 11 Topics: Axitinib; Carcinoma, Renal Cell; Drug Discovery; Drug Interactions; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors	2017
Individualized dosing with axitinib: rationale and practical guidance. Future oncology (London, England), 2018, Volume: 14, Issue:9 Topics: Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Molecular Targeted Therapy; Protein Kinase Inhibitors; Vascular Endothelial Growth Factor A	2018
Recent advances in colony stimulating factor-1 receptor/c-FMS as an emerging target for various therapeutic implications. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, Volume: 103 Topics: Amino Acid Sequence; Animals; Axitinib; Genes, fms; Humans; Imidazoles; Indazoles; Inflammation; Inflammation Mediators; Macrophage Colony-Stimulating Factor; Protein Structure, Secondary; Pyridines; Structure-Activity Relationship	2018
Bulletin du cancer, 2018, Volume: 105 Suppl 3 Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Immunotherapy; Indazoles; Kidney Neoplasms; Nivolumab; Phenylurea Compounds; Pyridines; Pyrimidines; Quinolines; Sulfonamides; Sunitinib	2018
Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. Cancer treatment reviews, 2020, Volume: 84 Topics: Angiogenesis Inhibitors; Anilides; Axitinib; Carcinoma, Renal Cell; Drug Interactions; Humans; Indazoles; Kidney Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib	2020
Second-line tyrosine kinase inhibitor-therapy after immunotherapy-failure. Current opinion in supportive and palliative care, 2020, Volume: 14, Issue:3 Topics: Anilides; Axitinib; Carcinoma, Renal Cell; Drug Therapy, Combination; Humans; Immunotherapy; Indazoles; Kidney Neoplasms; Neoplasm Metastasis; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases	2020
Targeted therapy for metastatic renal cell carcinoma. The Cochrane database of systematic reviews, 2020, 10-14, Volume: 10 Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Axitinib; Bevacizumab; Bias; Carcinoma, Renal Cell; Everolimus; Humans; Indazoles; Ipilimumab; Kidney Neoplasms; Phenylurea Compounds; Progression-Free Survival; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Quinolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2020
The multikinase inhibitor axitinib in the treatment of advanced hepatocellular carcinoma: the current clinical applications and the molecular mechanisms. Frontiers in immunology, 2023, Volume: 14 Topics: Axitinib; Carcinoma, Hepatocellular; Humans; Imidazoles; Indazoles; Liver Neoplasms; Programmed Cell Death 1 Receptor; Sorafenib; Vascular Endothelial Growth Factor A	2023

Trials

79 trial(s) available for indazoles and axitinib

Article	Year
Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-20, Volume: 23, Issue:24 Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Area Under Curve; Axitinib; Drug Administration Schedule; Drug Interactions; Female; Humans; Imidazoles; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neovascularization, Pathologic; Treatment Outcome	2005
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leukemia research, 2006, Volume: 30, Issue:7 Topics: Acute Disease; Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imidazoles; Immunohistochemistry; Indazoles; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Placenta Growth Factor; Predictive Value of Tests; Pregnancy Proteins; Prognosis; Proto-Oncogene Proteins c-kit; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2	2006
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. The Lancet. Oncology, 2007, Volume: 8, Issue:11 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Bone Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Enzyme Inhibitors; Female; Humans; Imidazoles; Indazoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Treatment Outcome	2007
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet (London, England), 2008, Jun-21, Volume: 371, Issue:9630 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Axitinib; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Receptors, Vascular Endothelial Growth Factor; Survival Rate	2008
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Oct-10, Volume: 26, Issue:29 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Female; Humans; Imidazoles; Indazoles; Male; Middle Aged; Receptors, Vascular Endothelial Growth Factor; Thyroid Neoplasms	2008
Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib. Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Quality of Life; Surveys and Questionnaires	2008
Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Aug-10, Volume: 27, Issue:23 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome	2009
Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers. Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:3 Topics: Adult; Area Under Curve; Asian People; Axitinib; Cross-Over Studies; Cytochrome P-450 CYP3A; Enzyme Inhibitors; Genotype; Glucuronosyltransferase; Humans; Imidazoles; Indazoles; Japan; Male; Metabolic Clearance Rate; Middle Aged; Rifampin; White People; Young Adult	2010
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Sep-20, Volume: 27, Issue:27 Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib	2009
CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone. British journal of cancer, 2009, Oct-06, Volume: 101, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Diastole; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Middle Aged; Pancreatic Neoplasms	2009
A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Imidazoles; Indazoles; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Treatment Outcome	2010
Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients. Cancer science, 2010, Volume: 101, Issue:4 Topics: Adult; Aged; Angiogenesis Inhibitors; Axitinib; Biomarkers; Fatigue; Female; Humans; Hypertension; Imidazoles; Indazoles; Male; Middle Aged; Neoplasms; Thyrotropin; Vascular Endothelial Growth Factor Receptor-2	2010
Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics. Investigational new drugs, 2011, Volume: 29, Issue:6 Topics: Administration, Oral; Adult; Angiogenesis Inhibitors; Axitinib; Case-Control Studies; Computer Simulation; Female; Humans; Imidazoles; Indazoles; Liver Diseases; Male; Middle Aged; Severity of Illness Index; Smoking	2011
Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers. Investigational new drugs, 2012, Volume: 30, Issue:1 Topics: Administration, Oral; Adult; Angiogenesis Inhibitors; Area Under Curve; Axitinib; Biotransformation; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Female; Genotype; Humans; Imidazoles; Indazoles; Ketoconazole; Male; Middle Aged; Phenotype; Single-Blind Method	2012
Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor. British journal of cancer, 2010, Nov-09, Volume: 103, Issue:10 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bilirubin; Creatinine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imidazoles; Indazoles; Male; Middle Aged; Neoplasms; Patient Selection; Receptors, Vascular Endothelial Growth Factor; Taxoids	2010
Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients. Investigational new drugs, 2012, Volume: 30, Issue:3 Topics: Adult; Aged; Angiogenesis Inhibitors; Asian People; Axitinib; Biomarkers; Fatigue; Female; Humans; Hyperthyroidism; Hypothyroidism; Imidazoles; Indazoles; Male; Middle Aged; Neoplasms; Proto-Oncogene Proteins c-kit; Thyroglobulin; Thyrotropin; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3	2012
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. The Lancet. Oncology, 2011, Volume: 12, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis	2011
Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jun-20, Volume: 29, Issue:18 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Hypertension; Imidazoles; Indazoles; Middle Aged; Mucositis; Neoplasm Proteins; Neutropenia; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Taxoids; Thrombophilia	2011
Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer. Investigational new drugs, 2012, Volume: 30, Issue:4 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Deoxycytidine; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms	2012
Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:17 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Proteinuria; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor Receptor-2	2011
Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Dec-01, Volume: 17, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Proto-Oncogene Proteins c-kit; Receptors, Vascular Endothelial Growth Factor	2011
A Phase I study to evaluate the pharmacokinetics of axitinib (AG-13736) in healthy Chinese volunteers. International journal of clinical pharmacology and therapeutics, 2011, Volume: 49, Issue:11 Topics: Adult; Angiogenesis Inhibitors; Area Under Curve; Axitinib; Female; Humans; Imidazoles; Indazoles; Male	2011
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (London, England), 2011, Dec-03, Volume: 378, Issue:9807 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Young Adult	2011
Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers. Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:1 Topics: Adult; Aged; Axitinib; Cross-Over Studies; Diarrhea; Dietary Fats; Energy Intake; Fasting; Fatigue; Female; Food-Drug Interactions; Humans; Imidazoles; Indazoles; Male; Middle Aged; Nausea; Tablets; Young Adult	2012
Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours. British journal of cancer, 2012, Oct-09, Volume: 107, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Imidazoles; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Treatment Outcome	2012
Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. British journal of cancer, 2012, Oct-09, Volume: 107, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Imidazoles; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Taxoids; Treatment Outcome	2012
Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand-foot skin reactions. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013, Volume: 21, Issue:3 Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Axitinib; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hand-Foot Syndrome; Heparin; Humans; Imidazoles; Indazoles; Indoles; Male; Middle Aged; Niacinamide; Ointments; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyrroles; Severity of Illness Index; Sorafenib; Sunitinib; Treatment Outcome	2013
Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib. Clinical genitourinary cancer, 2013, Volume: 11, Issue:2 Topics: Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Survival Rate; Treatment Outcome	2013
Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer. British journal of cancer, 2013, Apr-30, Volume: 108, Issue:8 Topics: Adult; Aged; Albumins; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoembryonic Antigen; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Keratin-19; Middle Aged; Multivariate Analysis; Oximes; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Piperazines; Prospective Studies; Quinazolines; Sirolimus; Sulfonamides; Survival Rate	2013
Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial. British journal of cancer, 2013, Apr-30, Volume: 108, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Self Report; Sorafenib; Treatment Outcome; Young Adult	2013
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. The Lancet. Oncology, 2013, Volume: 14, Issue:6 Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Intention to Treat Analysis; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Quality of Life; Sorafenib; Surveys and Questionnaires; Time Factors; Treatment Outcome	2013
Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study. Cancer, 2013, 07-15, Volume: 119, Issue:14 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Imidazoles; Indazoles; Infusions, Intravenous; Injections, Intravenous; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Treatment Outcome	2013
Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial. Japanese journal of clinical oncology, 2013, Volume: 43, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Asian People; Axitinib; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Hypertension; Hypothyroidism; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proteinuria; Sorafenib; Treatment Outcome; Young Adult	2013
Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. The Lancet. Oncology, 2013, Volume: 14, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Double-Blind Method; Europe; Female; Humans; Imidazoles; Indazoles; Japan; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Time Factors; Treatment Outcome; United States	2013
Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study. Clinical colorectal cancer, 2013, Volume: 12, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organoplatinum Compounds; Young Adult	2013
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. The Lancet. Oncology, 2013, Volume: 14, Issue:13 Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Confounding Factors, Epidemiologic; Disease-Free Survival; Europe; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; North America; Odds Ratio; Phenylurea Compounds; Protein Kinase Inhibitors; Research Design; Severity of Illness Index; Sorafenib; Treatment Outcome	2013
Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:1 Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Proportional Hazards Models; Treatment Outcome	2014
The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer. The Journal of clinical endocrinology and metabolism, 2014, Volume: 99, Issue:4 Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Angiogenesis Inhibitors; Axitinib; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Imidazoles; Indazoles; Receptors, Vascular Endothelial Growth Factor; Survival Analysis; Treatment Outcome; Tumor Burden; Vascular Endothelial Growth Factor A	2014
Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours. British journal of cancer, 2014, Feb-18, Volume: 110, Issue:4 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Female; Fluorodeoxyglucose F18; Fluorouracil; Gastrointestinal Neoplasms; Humans; Imidazoles; Indazoles; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Positron-Emission Tomography; Protein Kinase Inhibitors; Radiopharmaceuticals; Withholding Treatment	2014
Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. European urology, 2014, Volume: 66, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Biopsy; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Laparoscopy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nephrectomy; Prospective Studies; Protein Kinase Inhibitors; Quality of Life; Texas; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden	2014
Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial. Targeted oncology, 2015, Volume: 10, Issue:1 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Hypertension; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib	2015
Pharmacokinetics, metabolism, and excretion of [14C]axitinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in humans. Drug metabolism and disposition: the biological fate of chemicals, 2014, Volume: 42, Issue:5 Topics: Adult; Axitinib; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Feces; Humans; Imidazoles; Indazoles; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Middle Aged; Molecular Structure; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor	2014
Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer. BMC cancer, 2014, Apr-25, Volume: 14 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Female; Glutamates; Guanine; Humans; Imidazoles; Indazoles; Male; Middle Aged; Pemetrexed; Vascular Endothelial Growth Factor A	2014
Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. British journal of cancer, 2014, Jun-10, Volume: 110, Issue:12 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Cytokines; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; Tumor Burden	2014
Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. Cancer, 2014, 09-01, Volume: 120, Issue:17 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Papillary; Diarrhea; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quality of Life; Thyroid Neoplasms; Treatment Outcome	2014
Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour. European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:17 Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Humans; Imidazoles; Indazoles; Indoles; Male; MAP Kinase Signaling System; Mice, SCID; Middle Aged; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Solitary Fibrous Tumors; Sorafenib; Sulfonamides; Sunitinib; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2	2014
Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma. Cancer science, 2014, Volume: 105, Issue:12 Topics: Adult; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Imidazoles; Indazoles; Japan; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Vascular Endothelial Growth Factor Receptor-2	2014
A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses. Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:6 Topics: Adult; Aged, 80 and over; Antineoplastic Agents; Axitinib; Disease-Free Survival; Follow-Up Studies; Humans; Imidazoles; Indazoles; Middle Aged; Protein Kinase Inhibitors; Survival Rate; Thyroid Neoplasms; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A	2014
Population pharmacokinetic-pharmacodynamic modelling of 24-h diastolic ambulatory blood pressure changes mediated by axitinib in patients with metastatic renal cell carcinoma. Clinical pharmacokinetics, 2015, Volume: 54, Issue:4 Topics: Aged; Algorithms; Axitinib; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Linear Models; Male; Middle Aged; Protein Kinase Inhibitors	2015
A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma. Cancer, 2015, May-15, Volume: 121, Issue:10 Topics: Adult; Aged; alpha-Fetoproteins; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Selection; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Recurrence; Treatment Outcome; Vascular Endothelial Growth Factor A	2015
Effect of axitinib on the QT interval in healthy volunteers. Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:3 Topics: Adult; Axitinib; Cross-Over Studies; Cytochrome P-450 CYP3A Inhibitors; Electrocardiography; Female; Heart Rate; Humans; Imidazoles; Indazoles; Ketoconazole; Male; Models, Biological; Protein Kinase Inhibitors; Single-Blind Method	2015
Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial. Japanese journal of clinical oncology, 2015, Volume: 45, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Deoxycytidine; Disease-Free Survival; European Union; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Japan; Kaplan-Meier Estimate; Male; Middle Aged; North America; Odds Ratio; Pancreatic Neoplasms; Treatment Outcome	2015
Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:7 Topics: Axitinib; Blood Pressure; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Survival Rate; Tissue Distribution	2015
Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma. Clinical genitourinary cancer, 2015, Volume: 13, Issue:4 Topics: Aged; Angiogenesis Inhibitors; Axitinib; Blood Pressure; Carcinoma, Renal Cell; Disease-Free Survival; Female; Genetic Association Studies; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Linkage Disequilibrium; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Proportional Hazards Models; Sorafenib; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2	2015
The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial. British journal of cancer, 2015, Apr-14, Volume: 112, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carboplatin; Dideoxynucleosides; Female; Humans; Imidazoles; Indazoles; Male; Melanoma; Middle Aged; Paclitaxel; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Radiography; Treatment Outcome	2015
Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer. BMC cancer, 2015, May-01, Volume: 15 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Middle Aged; Protein Kinase Inhibitors; Vascular Endothelial Growth Factor A	2015
Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with (18)F-3'deoxy-3'fluoro-L-thymidine positron emission tomography/computed tomography. Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:1 Topics: Adult; Aged; Axitinib; Dideoxynucleosides; Disease Progression; Female; Fluorine Radioisotopes; Humans; Imidazoles; Indazoles; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Protein Kinase Inhibitors; Radiopharmaceuticals; Substance Withdrawal Syndrome; Tomography, X-Ray Computed; Vascular Endothelial Growth Factor A	2015
Variability of inter-observer agreement on feasibility of partial nephrectomy before and after neoadjuvant axitinib for locally advanced renal cell carcinoma (RCC): independent analysis from a phase II trial. BJU international, 2016, Volume: 117, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Feasibility Studies; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Observer Variation	2016
Long-Term Safety With Axitinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma. Clinical genitourinary cancer, 2015, Volume: 13, Issue:6 Topics: Axitinib; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Protein Kinase Inhibitors; Retrospective Studies	2015
Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Axitinib; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Imidazoles; Indazoles; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Palliative Care; Survival Rate; Treatment Outcome	2015
Acceleration of Proteinuria without Significant Impact on Renal Function and Its Protection by Angiotensin II Receptor Blocker in Rats Treated with Axitinib. Targeted oncology, 2016, Volume: 11, Issue:3 Topics: Angiotensin Receptor Antagonists; Animals; Axitinib; Humans; Imidazoles; Indazoles; Kidney; Protein Kinase Inhibitors; Proteinuria; Rats; Rats, Sprague-Dawley	2016
Clinical and Translational Assessment of VEGFR1 as a Mediator of the Premetastatic Niche in High-Risk Localized Prostate Cancer. Molecular cancer therapeutics, 2015, Volume: 14, Issue:12 Topics: Aged; Axitinib; Disease-Free Survival; Humans; Imidazoles; Indazoles; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Vascular Endothelial Growth Factor Receptor-1	2015
A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer. Investigational new drugs, 2015, Volume: 33, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Axitinib; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Hypertension; Imidazoles; Indazoles; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Survival Rate	2015
A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2016, Volume: 11, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Cisplatin; Female; Follow-Up Studies; Humans; Imidazoles; Indazoles; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Neoplasm Staging; Pemetrexed; Pleural Neoplasms; Prognosis; Survival Rate	2016
Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma. Journal of neuro-oncology, 2016, Volume: 128, Issue:1 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Axitinib; Bevacizumab; Brain Neoplasms; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Glioblastoma; Humans; Imidazoles; Indazoles; Lomustine; Male; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Radiopharmaceuticals; Steroids; Treatment Outcome; Young Adult	2016
Detection of Early Tumor Response to Axitinib in Advanced Hepatocellular Carcinoma by Dynamic Contrast Enhanced Ultrasound. Ultrasound in medicine & biology, 2016, Volume: 42, Issue:6 Topics: Adolescent; Adult; Aged; Axitinib; Carcinoma, Hepatocellular; Contrast Media; Disease-Free Survival; Female; Humans; Image Enhancement; Imidazoles; Indazoles; Liver; Liver Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Treatment Outcome; Ultrasonography; Young Adult	2016
A phase II study of axitinib in advanced neuroendocrine tumors. Endocrine-related cancer, 2016, Volume: 23, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Colonic Neoplasms; Female; Humans; Hypertension; Imidazoles; Indazoles; Intestinal Neoplasms; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Protein Kinase Inhibitors; Rectal Neoplasms; Thymus Neoplasms; Treatment Outcome	2016
Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion. Cancer immunology, immunotherapy : CII, 2016, Volume: 65, Issue:6 Topics: Adult; Aged; Angiogenesis Inhibitors; Antigens, CD; Axitinib; Biomarkers; Cell Line, Tumor; Cytokines; Disease Progression; Female; Glioblastoma; Hepatitis A Virus Cellular Receptor 2; Humans; Imidazoles; Immunologic Memory; Immunomodulation; Immunophenotyping; Indazoles; Lymphocyte Activation Gene 3 Protein; Lymphocyte Count; Male; Middle Aged; Neoplasm Recurrence, Local; Phenotype; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory	2016
Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma. Clinical genitourinary cancer, 2016, Volume: 14, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Double Bind Interaction; Drug Administration Schedule; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome	2016
Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial. Clinical genitourinary cancer, 2017, Volume: 15, Issue:1 Topics: Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Survival Analysis; Treatment Outcome	2017
A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:10 Topics: Adult; Aged; Axitinib; Carcinoma, Adenoid Cystic; Chromosomes, Human, Pair 4; Disease-Free Survival; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; High-Throughput Nucleotide Sequencing; Humans; Imidazoles; Indazoles; Male; Middle Aged; NFI Transcription Factors; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myb	2016
Overall survival of first-line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study. Cancer science, 2017, Volume: 108, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Double-Blind Method; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Treatment Outcome	2017
A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients. CPT: pharmacometrics & systems pharmacology, 2017, Volume: 6, Issue:6 Topics: Antineoplastic Agents; Axitinib; Biomarkers, Tumor; Blood Pressure; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Models, Biological; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Treatment Outcome; Tumor Burden; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3	2017
A Phase-2 Trial of Single Agent Axitinib as Maintenance Therapy Following First-Line Treatment With Modified FOLFOX/Bevacizumab in Patients With Metastatic Colorectal Cancer. Cancer investigation, 2017, Jul-03, Volume: 35, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Treatment Outcome	2017
Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated BMC cancer, 2017, 06-02, Volume: 17, Issue:1 Topics: Adult; Aged; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Cell Proliferation; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Imidazoles; Indazoles; Indoles; London; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Neoplasms, Second Primary; Positron-Emission Tomography; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Outcome	2017
A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma. Cancer, 2017, Oct-15, Volume: 123, Issue:20 Topics: Aged; Alanine Transaminase; Alkaline Phosphatase; Antineoplastic Agents; Axitinib; Bilirubin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; International Normalized Ratio; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Survival Rate; Treatment Outcome; Tumor Burden	2017
Axitinib for Gemcitabine-refractory Advanced Biliary Tract Cancer: Report of 5 Cases. Anticancer research, 2017, Volume: 37, Issue:7 Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Biliary Tract Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Lymph Nodes; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Protein Kinase Inhibitors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden	2017
Presurgical axitinib therapy increases fibrotic reactions within tumor thrombus in renal cell carcinoma with thrombus extending to the inferior vena cava. International journal of clinical oncology, 2018, Volume: 23, Issue:1 Topics: Aged; Axitinib; Blood Loss, Surgical; Carcinoma, Renal Cell; Female; Fibrosis; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Postoperative Complications; Preoperative Care; Retrospective Studies; Thrombosis; Vena Cava, Inferior; Venous Thrombosis	2018
Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study. European journal of cancer (Oxford, England : 1990), 2017, Volume: 85 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Diffusion Magnetic Resonance Imaging; Drug Dosage Calculations; Everolimus; Female; France; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Time Factors; Treatment Outcome	2017

Other Studies

249 other study(ies) available for indazoles and axitinib

Article	Year
Imaging and other biomarkers in early clinical studies: one step at a time or re-engineering drug development? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-20, Volume: 23, Issue:24 Topics: Administration, Oral; Angiogenesis Inhibitors; Axitinib; Biomarkers, Tumor; Clinical Trials as Topic; Diagnostic Imaging; Drug Design; Drugs, Investigational; Humans; Imidazoles; Indazoles; Neoplasms; Neovascularization, Pathologic	2005
Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI. Journal of magnetic resonance imaging : JMRI, 2005, Volume: 22, Issue:4 Topics: Animals; Axitinib; Breast Neoplasms; Female; Humans; Image Enhancement; Imidazoles; Indazoles; Magnetic Resonance Imaging; Mice; Mice, Nude; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Transplantation, Heterologous	2005
Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. American journal of physiology. Heart and circulatory physiology, 2006, Volume: 290, Issue:2 Topics: Animals; Apoptosis; Axitinib; Basement Membrane; Capillaries; Collagen Type IV; Endothelial Cells; Imidazoles; Indazoles; Mice; Mice, Inbred Strains; Pericytes; Platelet Endothelial Cell Adhesion Molecule-1; Signal Transduction; Trachea; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Patency	2006
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. American journal of physiology. Heart and circulatory physiology, 2006, Volume: 290, Issue:2 Topics: Aging; Animals; Axitinib; Blood Pressure; Capillaries; Carcinoma, Lewis Lung; Glucose Tolerance Test; Heart; Imidazoles; Indazoles; Islets of Langerhans; Kidney; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neoplasm Transplantation; Pancreatic Neoplasms; Phenotype; Reference Values; Regeneration; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2	2006
Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer research, 2006, Feb-01, Volume: 66, Issue:3 Topics: Adenoma, Islet Cell; Animals; Antibodies, Neoplasm; Axitinib; Cadherins; Carcinoma, Lewis Lung; Fibrin; Imidazoles; Immunoglobulin G; Indazoles; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microspheres; Neovascularization, Pathologic; Signal Transduction; Vascular Endothelial Growth Factor A	2006
Antiangiogenic therapy decreases integrin expression in normalized tumor blood vessels. Cancer research, 2006, Mar-01, Volume: 66, Issue:5 Topics: Adenoma, Islet Cell; Animals; Axitinib; Bacteriophage M13; Endothelial Cells; Female; Imidazoles; Indazoles; Integrin alpha5beta1; Integrin alphaVbeta3; Male; Mice; Mice, Transgenic; Microscopy, Fluorescence; Neovascularization, Pathologic; Oligopeptides; Pancreatic Neoplasms; Substrate Specificity	2006
Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU international, 2006, Volume: 98, Issue:4 Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Mutation; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; von Hippel-Lindau Disease	2006
Rapid vascular regrowth in tumors after reversal of VEGF inhibition. The Journal of clinical investigation, 2006, Volume: 116, Issue:10 Topics: Actins; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Axitinib; Basement Membrane; Blood Vessels; Carcinoma, Lewis Lung; Collagen Type IV; Endothelium, Vascular; Imidazoles; Indazoles; Insulinoma; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neoplasms; Neovascularization, Pathologic; Organic Chemicals; Pericytes; Platelet Endothelial Cell Adhesion Molecule-1; Receptor, Platelet-Derived Growth Factor beta; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2006
AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magnetic resonance imaging, 2007, Volume: 25, Issue:3 Topics: Animals; Antineoplastic Agents; Axitinib; Breast Neoplasms; Capillary Permeability; Cell Proliferation; Contrast Media; Female; Imidazoles; Indazoles; Magnetic Resonance Imaging; Mice; Mice, Nude; Neovascularization, Pathologic; Receptors, Vascular Endothelial Growth Factor; src-Family Kinases; Treatment Outcome	2007
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer, 2007, Aug-01, Volume: 110, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A	2007
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3. IDrugs : the investigational drugs journal, 2007, Volume: 10, Issue:8 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Biomedical Research; Breast Neoplasms; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Molecular Structure; Neoplasms; Organoplatinum Compounds; Pancreatic Neoplasms; Piperidines; Prednisolone; Prostatic Neoplasms; Quinazolines; Treatment Outcome	2007
The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature. Cancer research, 2007, Oct-15, Volume: 67, Issue:20 Topics: Actins; Angiogenesis Inhibitors; Animals; Apoptosis; Axitinib; Cell Growth Processes; Cell Hypoxia; Collagen Type IV; Combined Modality Therapy; Dose Fractionation, Radiation; Humans; Imidazoles; Indazoles; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Prostatic Neoplasms; Receptor, Platelet-Derived Growth Factor beta; Xenograft Model Antitumor Assays	2007
Targeting VEGF receptors in kidney cancer. The Lancet. Oncology, 2007, Volume: 8, Issue:11 Topics: Axitinib; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Mutation; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Von Hippel-Lindau Tumor Suppressor Protein	2007
Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Molecular cancer therapeutics, 2008, Volume: 7, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Cell Line, Tumor; Cyclophosphamide; Gene Expression Regulation, Neoplastic; Imidazoles; Indazoles; Liver; Mice; Mice, Inbred ICR; Neoplasms; Rats; Thrombospondin 1; Xenograft Model Antitumor Assays	2008
Targeting angiogenesis in pancreatic cancer. Lancet (London, England), 2008, Jun-21, Volume: 371, Issue:9630 Topics: Angiogenesis Inhibitors; Axitinib; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Imidazoles; Indazoles; Pancreatic Neoplasms; Protein-Tyrosine Kinases; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor	2008
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. The Journal of urology, 2008, Volume: 180, Issue:3 Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chi-Square Distribution; DNA Primers; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A; von Hippel-Lindau Disease	2008
Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Nov-15, Volume: 14, Issue:22 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Blotting, Western; Cell Line, Tumor; Drug Synergism; Female; Humans; Imidazoles; Immunohistochemistry; Immunoprecipitation; Indazoles; Mice; Mice, Nude; Neoplasms, Experimental; Neovascularization, Pathologic; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Xenograft Model Antitumor Assays	2008
Axitinib induces paradoxical erythropoietin synthesis in metastatic renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jan-20, Volume: 27, Issue:3 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Erythropoietin; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases	2009
Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Jan-15, Volume: 15, Issue:2 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzimidazoles; Cell Line, Tumor; Cyclophosphamide; Genes, Dominant; Humans; Imidazoles; Indazoles; Male; Mice; Mice, Inbred ICR; Mice, SCID; Neoplasm Transplantation; Prostatic Neoplasms	2009
Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors. Cancer research, 2009, May-15, Volume: 69, Issue:10 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Axitinib; Benzamides; Humans; Imatinib Mesylate; Imidazoles; Immunoglobulin Fc Fragments; Indazoles; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Transgenic; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1	2009
Characterizing the effects of the juxtamembrane domain on vascular endothelial growth factor receptor-2 enzymatic activity, autophosphorylation, and inhibition by axitinib. Biochemistry, 2009, Jul-28, Volume: 48, Issue:29 Topics: Axitinib; Calorimetry; Catalytic Domain; Cell Line; Chromatography, Liquid; Gastrins; Humans; Imidazoles; Indazoles; Kinetics; Phosphorylation; Surface Plasmon Resonance; Tandem Mass Spectrometry; Vascular Endothelial Growth Factor Receptor-2	2009
Alterations in daily sequencing of axitinib and fractionated radiotherapy do not affect tumor growth inhibition or pathophysiological response. Radiation research, 2009, Volume: 171, Issue:5 Topics: Axitinib; Basement Membrane; Cell Line, Tumor; Combined Modality Therapy; Dose Fractionation, Radiation; Humans; Imidazoles; Indazoles; Male; Neoplasms; Pericytes; Protein Kinase Inhibitors	2009
Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor. Targeted oncology, 2009, Volume: 4, Issue:4 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Axitinib; Disease Models, Animal; Drug Delivery Systems; Imidazoles; Indazoles; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2009
Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2009, Dec-15, Volume: 877, Issue:32 Topics: Animals; Axitinib; Chromatography, Liquid; Humans; Imidazoles; Indazoles; Limit of Detection; Mice; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Tandem Mass Spectrometry; Tissue Distribution	2009
Development of a targeted polymorph screening approach for a complex polymorphic and highly solvating API. Journal of pharmaceutical sciences, 2010, Volume: 99, Issue:9 Topics: Axitinib; Computer Simulation; Crystallization; Crystallography, X-Ray; Hydrogen Bonding; Imidazoles; Indazoles; Models, Molecular; Molecular Conformation; Pharmaceutical Preparations	2010
A thermodynamic-based approach to analyzing a highly solvating polymorphic system: the desolvation window method. Journal of pharmaceutical sciences, 2011, Volume: 100, Issue:1 Topics: Antineoplastic Agents; Axitinib; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Imidazoles; Indazoles; Isomerism; Kinetics; Phase Transition; Piperazines; Powder Diffraction; Solubility; Solvents; Technology, Pharmaceutical; Temperature; Thermodynamics; Thiazoles; Transition Temperature; Water	2011
The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts. International journal of cancer, 2011, Jun-01, Volume: 128, Issue:11 Topics: Animals; Apoptosis; Axitinib; Blotting, Western; Bone Marrow Neoplasms; Child; Drug Synergism; Endothelium, Vascular; Humans; Imidazoles; Indazoles; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Neuroblastoma; Phosphorylation; Sirolimus; Stem Cells; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3; Xenograft Model Antitumor Assays	2011
Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics. Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:5 Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Axitinib; Biological Transport; Blood-Brain Barrier; Brain; Breast Neoplasms; Cell Line; Dogs; Female; Humans; Imidazoles; Indazoles; Male; Mice; Mice, Knockout; Protein Kinase Inhibitors	2011
Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. Neoplasia (New York, N.Y.), 2011, Volume: 13, Issue:3 Topics: Adenosine Triphosphatases; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Axitinib; Blotting, Western; Camptothecin; Cation Transport Proteins; Cell Proliferation; Cells, Cultured; Copper-Transporting ATPases; Drug Synergism; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Humans; Imidazoles; Immunoenzyme Techniques; Indazoles; Irinotecan; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Proteins; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thrombospondins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2011
Rapid identification and absence of drug tests for AG-013736 in 1mg Axitinib tablets by ion mobility spectrometry and DART™ mass spectrometry. Journal of pharmaceutical and biomedical analysis, 2011, Jun-01, Volume: 55, Issue:3 Topics: Antineoplastic Agents; Axitinib; Drugs, Investigational; Imidazoles; Indazoles; Mass Spectrometry; Molecular Structure; Placebos; Tablets; Time Factors	2011
Antiangiogenesis enhances intratumoral drug retention. Cancer research, 2011, Apr-01, Volume: 71, Issue:7 Topics: Angiogenesis Inhibitors; Animals; Axitinib; Cell Line, Tumor; Cyclophosphamide; Drug Synergism; Gliosarcoma; Imidazoles; Indazoles; Male; Mice; Mice, Inbred ICR; Mice, SCID; Neovascularization, Pathologic; Random Allocation; Rats; Receptors, Vascular Endothelial Growth Factor; Transplantation, Heterologous	2011
The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells. The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:6 Topics: Anilides; Axitinib; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Indazoles; Indoles; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sunitinib; Thyroid Gland; Tumor Cells, Cultured	2011
Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Jun-01, Volume: 17, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Blood Pressure; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Male; Middle Aged; Neoplasms; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3	2011
Anti-vascular endothelial growth factor therapy for breast cancer: can we pick the winners? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jun-20, Volume: 29, Issue:18 Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Female; Guidelines as Topic; Humans; Imidazoles; Indazoles; Multicenter Studies as Topic; Neoplasm Proteins; Precision Medicine; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Research Design; Taxoids; Vascular Endothelial Growth Factor A	2011
Managing refractory metastatic renal cell carcinoma: a RECORD spinning on a tilted AXIS. Clinical genitourinary cancer, 2011, Volume: 9, Issue:1 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Management; Everolimus; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Sirolimus; Treatment Failure	2011
Tilting the AXIS towards therapeutic limits in renal cancer. Lancet (London, England), 2011, Dec-03, Volume: 378, Issue:9807 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib	2011
Axitinib modulates hypoxia-induced blood-retina barrier permeability and expression of growth factors. Growth factors (Chur, Switzerland), 2012, Volume: 30, Issue:1 Topics: Adult; Aged; Axitinib; Blood-Retinal Barrier; Cell Hypoxia; Cell Membrane Permeability; Cell Survival; Cells, Cultured; Diabetic Retinopathy; Human Umbilical Vein Endothelial Cells; Humans; Imidazoles; Indazoles; Intercellular Signaling Peptides and Proteins; Macular Edema; Middle Aged; Pigment Epithelium of Eye; Receptor, Platelet-Derived Growth Factor beta; RNA, Messenger; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1	2012
Drug approvals 2011: focus on companion diagnostics. Journal of the National Cancer Institute, 2012, Jan-18, Volume: 104, Issue:2 Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Biomarkers, Tumor; Brentuximab Vedotin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crizotinib; Drug Approval; Female; Humans; Imidazoles; Immunoconjugates; Indazoles; Indoles; Ipilimumab; Lung Neoplasms; Male; Melanoma; Molecular Targeted Therapy; Neoplasms; Piperidines; Prostatic Neoplasms; Pyrazoles; Pyridines; Quinazolines; Rare Diseases; Sulfonamides; Survival Analysis; United States; United States Food and Drug Administration; Vemurafenib	2012
VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression. Cancer research, 2012, Mar-01, Volume: 72, Issue:5 Topics: Administration, Metronomic; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Axitinib; Brain Neoplasms; Cell Line, Tumor; Cyclophosphamide; Glioblastoma; Humans; Imidazoles; Immunity, Innate; Indazoles; Male; Maximum Tolerated Dose; Mice; Mice, Inbred NOD; Mice, SCID; Perforin; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays	2012
Metastatic renal cell carcinoma treated sequentially with multiple VEGF receptor-targeted inhibitors--a case report. Anticancer research, 2012, Volume: 32, Issue:2 Topics: Angiogenesis Inhibitors; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib	2012
VEGF-induced growth cone enhancement is diminished by inhibiting tyrosine-residue 1214 of VEGFR-2. Cells, tissues, organs, 2012, Volume: 196, Issue:3 Topics: Animals; Antibodies, Blocking; Axitinib; Axons; Blotting, Western; Cell Movement; Cells, Cultured; Chick Embryo; Chickens; Ganglia, Spinal; Growth Cones; Imidazoles; Indazoles; Mice; Microscopy, Confocal; Neurons; Protein Kinase Inhibitors; Signal Transduction; Tyrosine; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2012
Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model. Melanoma research, 2012, Volume: 22, Issue:3 Topics: Angiogenesis Inhibitors; Animals; Axitinib; Cancer Vaccines; Cell Line, Tumor; Combined Modality Therapy; Dendritic Cells; Endothelial Cells; Female; Imidazoles; Indazoles; Interleukin-12; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Melanoma; Mice; Mice, Inbred C57BL; Ovalbumin; Peptide Fragments; Protein Kinase Inhibitors; Skin Neoplasms; T-Lymphocytes; Time Factors; Tumor Burden; Tumor Microenvironment	2012
Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2. Molecular medicine (Cambridge, Mass.), 2012, Jul-18, Volume: 18 Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Axitinib; Biological Transport; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Indazoles; Male; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Proteins; Neoplasms; Neoplastic Stem Cells; Phosphorylation; Proto-Oncogene Proteins c-akt; Xenograft Model Antitumor Assays	2012
Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer discovery, 2012, Volume: 2, Issue:4 Topics: AMP-Activated Protein Kinases; Animals; Axitinib; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Synergism; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Indazoles; Melanoma; Metformin; Mice; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Ribosomal Protein S6 Kinases; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2012
Second-line therapy after VEGF targeted therapy in metastatic renal cancer: a law of diminishing returns. Clinical genitourinary cancer, 2012, Volume: 10, Issue:2 Topics: Angiogenesis Inhibitors; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A	2012
Case of complete response to everolimus for metastatic renal cell carcinoma. International journal of urology : official journal of the Japanese Urological Association, 2012, Volume: 19, Issue:9 Topics: Abdominal Cavity; Acute Kidney Injury; Axitinib; Carcinoma, Renal Cell; Combined Modality Therapy; Everolimus; Humans; Imidazoles; Immunosuppressive Agents; Indazoles; Interferon-alpha; Kidney Neoplasms; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nephrectomy; Protein Kinase Inhibitors; Remission Induction; Sirolimus; Tomography, X-Ray Computed; Withholding Treatment	2012
Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma. Japanese journal of clinical oncology, 2012, Volume: 42, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thyroid Diseases; Thyroid Gland; Thyrotoxicosis	2012
Axitinib (Inlyta) for advanced renal cell carcinoma. The Medical letter on drugs and therapeutics, 2012, Jun-11, Volume: 54, Issue:1392 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms	2012
[Therapeutic effect of axitinib and 5-FU in nude mice bearing human colon cancer xenograft]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2012, Volume: 32, Issue:6 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Cell Line, Tumor; Colonic Neoplasms; Female; Fluorouracil; Humans; Imidazoles; Indazoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Xenograft Model Antitumor Assays	2012
Rational coformer or solvent selection for pharmaceutical cocrystallization or desolvation. Journal of pharmaceutical sciences, 2012, Volume: 101, Issue:10 Topics: Axitinib; Chemistry, Pharmaceutical; Crystallization; Imidazoles; Indazoles; Models, Chemical; Pharmaceutical Preparations; Protein Kinase Inhibitors; Solubility; Solvents; Thermodynamics; Thiophanate	2012
Antiangiogenic effects of axitinib, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, on laser-induced choroidal neovascularization in mice. Current eye research, 2013, Volume: 38, Issue:1 Topics: Animals; Axitinib; Choroid; Choroidal Neovascularization; Disease Models, Animal; Imidazoles; Indazoles; Laser Coagulation; Male; Mice; Mice, Inbred C57BL; Microscopy, Confocal; Protein Kinase Inhibitors; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1	2013
Close intramolecular sulfur-oxygen contacts: modified force field parameters for improved conformation generation. Journal of computer-aided molecular design, 2012, Volume: 26, Issue:11 Topics: Algorithms; Axitinib; Databases, Factual; Humans; Imidazoles; Indazoles; Models, Chemical; Models, Molecular; Molecular Conformation; Molecular Dynamics Simulation; Oxygen; Protein Kinase Inhibitors; Sulfur	2012
Inappropriate elevation of serum thyrotropin levels in patients treated with axitinib. Thyroid : official journal of the American Thyroid Association, 2013, Volume: 23, Issue:4 Topics: Aged; Aged, 80 and over; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Thyroid Function Tests; Thyroiditis; Thyrotoxicosis; Thyrotropin	2013
Active tuberculosis during temsirolimus and bevacizumab treatment. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-10, Volume: 31, Issue:2 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Randomized Controlled Trials as Topic; Sirolimus; Tuberculosis	2013
Axitinib: in advanced, treatment-experienced renal cell carcinoma. Drugs, 2012, Dec-24, Volume: 72, Issue:18 Topics: Axitinib; Carcinoma, Renal Cell; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome	2012
Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantrone. The Journal of pharmacology and experimental therapeutics, 2013, Volume: 344, Issue:2 Topics: Angiogenesis Inhibitors; Animals; Anthraquinones; Antineoplastic Agents; Axitinib; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Hydralazine; Imidazoles; Indazoles; Male; Mice; Mice, Nude; Mice, SCID; NAD(P)H Dehydrogenase (Quinone); Neoplasms; Neovascularization, Pathologic; Rats; Regional Blood Flow; Vasodilator Agents; Xenograft Model Antitumor Assays	2013
Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors. Pancreas, 2013, Volume: 42, Issue:3 Topics: Axitinib; Benzoquinones; Biomarkers, Tumor; Carcinoid Tumor; Cell Line, Tumor; Cell Survival; Drug Therapy; ErbB Receptors; HSP90 Heat-Shock Proteins; Humans; Imidazoles; Immunohistochemistry; In Situ Hybridization, Fluorescence; Indazoles; Lactams, Macrocyclic; Mutation; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins p21(ras); Pyrazoles; ras Proteins; Receptor, ErbB-2; Receptor, IGF Type 1; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Transforming Growth Factor-beta Type I; Receptors, Somatostatin; Receptors, Transforming Growth Factor beta; Triazines; Vascular Endothelial Growth Factor Receptor-1	2013
New drugs 2013, Part I. Nursing, 2013, Volume: 43, Issue:2 Topics: Aminophenols; Anilides; Antibodies, Monoclonal, Humanized; Axitinib; Benzodiazepines; Carbamates; Clobazam; Diterpenes; Drug Approval; gamma-Glutamyl Hydrolase; Glucosylceramidase; Humans; Imidazoles; Indans; Indazoles; Peptides; Phenylenediamines; Prostaglandins F; Pyridines; Quinolones	2013
A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma. Cancer treatment reviews, 2013, Volume: 39, Issue:4 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2013
Lenticular cytoprotection. Part 1: the role of hypoxia inducible factors-1α and -2α and vascular endothelial growth factor in lens epithelial cell survival in hypoxia. Molecular vision, 2013, Volume: 19 Topics: Axitinib; Basic Helix-Loop-Helix Transcription Factors; Cell Hypoxia; Cell Line; Cell Survival; Epithelial Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imidazoles; Indazoles; Lens, Crystalline; MAP Kinase Signaling System; Models, Molecular; Protein Synthesis Inhibitors; Proto-Oncogene Proteins c-bcl-2; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Topotecan; Vascular Endothelial Growth Factor A	2013
Axitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomes. American journal of clinical oncology, 2014, Volume: 37, Issue:4 Topics: Axitinib; Carcinoma, Renal Cell; Diarrhea; Dysphonia; Fatigue; Humans; Hypertension; Imidazoles; Indazoles; Kidney Neoplasms; Nausea; Protein Kinase Inhibitors; Proteinuria; Vomiting	2014
[Multikinase inhibitors as a new approach in neovascular age-related macular degeneration (AMD) treatment: in vitro safety evaluations of axitinib, pazopanib and sorafenib for intraocular use]. Klinische Monatsblatter fur Augenheilkunde, 2013, Volume: 230, Issue:3 Topics: Angiogenesis Inhibitors; Astrocytes; Axitinib; Cell Survival; Cornea; Dose-Response Relationship, Drug; Endothelial Cells; Endothelium, Corneal; Humans; Imidazoles; Indazoles; Lens, Crystalline; Microscopy, Phase-Contrast; Niacinamide; Optic Disk; Organ Culture Techniques; Oxidative Stress; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Retinal Pigment Epithelium; Sorafenib; Sulfonamides; Trabecular Meshwork; Wet Macular Degeneration	2013
Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. Journal of clinical pharmacology, 2013, Volume: 53, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Models, Biological; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Young Adult	2013
New options for second-line therapy of advanced renal cancer. The Lancet. Oncology, 2013, Volume: 14, Issue:6 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib	2013
Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors. The Journal of biological chemistry, 2013, Jun-07, Volume: 288, Issue:23 Topics: Antigens, CD; Apoptosis; Axitinib; CD8-Positive T-Lymphocytes; Female; G2 Phase Cell Cycle Checkpoints; Humans; Imidazoles; Immunosuppressive Agents; Indazoles; Jurkat Cells; M Phase Cell Cycle Checkpoints; Male; Membrane Potential, Mitochondrial; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Receptors, CCR7; Receptors, CXCR3	2013
Impact of tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell-derived tumor model. Molecular cancer therapeutics, 2013, Volume: 12, Issue:5 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Axitinib; Cell Line, Tumor; Disease Models, Animal; Humans; Hypoxia; Imidazoles; Indazoles; Male; Neoplastic Stem Cells; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Sorafenib; Xenograft Model Antitumor Assays	2013
Axitinib controlled metastatic renal cell carcinoma for 5 years. Japanese journal of clinical oncology, 2013, Volume: 43, Issue:7 Topics: Aged; Antineoplastic Agents; Asian People; Axitinib; Brain Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Protein Kinase Inhibitors; Seizures; Tomography, X-Ray Computed; Treatment Outcome	2013
In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions. Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:8 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Autoradiography; Axitinib; Caco-2 Cells; Drug Interactions; Hepatocytes; Humans; Imidazoles; Indazoles; Liver; Mice; Neoplasm Proteins; Permeability; Protein Kinase Inhibitors; Risk Assessment; Solubility	2013
Population pharmacokinetic analysis of axitinib in healthy volunteers. British journal of clinical pharmacology, 2014, Volume: 77, Issue:3 Topics: Adult; Angiogenesis Inhibitors; Aryl Hydrocarbon Hydroxylases; Axitinib; Biotransformation; Body Weight; Clinical Trials, Phase I as Topic; Cytochrome P-450 CYP2C19; Drug Dosage Calculations; Female; Genotype; Glucuronosyltransferase; Healthy Volunteers; Humans; Imidazoles; Indazoles; Male; Middle Aged; Models, Biological; Nonlinear Dynamics; Pharmacogenetics; Phenotype; Protein Kinase Inhibitors; Young Adult	2014
Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis. The oncologist, 2013, Volume: 18, Issue:8 Topics: Axitinib; Blood Pressure; Clinical Trials as Topic; Combined Modality Therapy; Erythrocyte Count; Erythropoiesis; Erythropoietin; Fluorouracil; Humans; Imidazoles; Indazoles; Neoplasms; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A	2013
Stratification of 18F-labeled PET imaging agents for the assessment of antiangiogenic therapy responses in tumors. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2013, Volume: 54, Issue:9 Topics: Angiogenesis Inhibitors; Animals; Axitinib; Cell Line, Tumor; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Imidazoles; Indazoles; Isotope Labeling; Mice; Neoplasms, Experimental; Peptides, Cyclic; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome	2013
Pharmacologic characterization of a kinetic in vitro human co-culture angiogenesis model using clinically relevant compounds. Journal of biomolecular screening, 2013, Volume: 18, Issue:10 Topics: Angiogenesis Inhibitors; Axitinib; Biomarkers; Cells, Cultured; Coculture Techniques; Drug Evaluation, Preclinical; Fibroblast Growth Factor 2; Green Fluorescent Proteins; Human Umbilical Vein Endothelial Cells; Humans; Imidazoles; Indazoles; Inhibitory Concentration 50; Kinetics; Neovascularization, Pathologic; Vascular Endothelial Growth Factor A	2013
Growth factor-mediated mesodermal cell guidance and skeletogenesis during sea urchin gastrulation. Development (Cambridge, England), 2013, Volume: 140, Issue:20 Topics: Animals; Apoptosis; Axitinib; Bone and Bones; Cell Differentiation; Cell Movement; Embryo Culture Techniques; Embryo, Nonmammalian; Fibroblast Growth Factors; Gastrulation; Gene Expression Regulation, Developmental; Imidazoles; Indazoles; Lytechinus; Mesoderm; Osteogenesis; Signal Transduction; Vascular Endothelial Growth Factor A; Zebrafish Proteins	2013
Axitinib, a selective inhibitor of vascular endothelial growth factor receptor, exerts an anticancer effect in melanoma through promoting antitumor immunity. Anti-cancer drugs, 2014, Volume: 25, Issue:2 Topics: Animals; Antineoplastic Agents; Apoptosis; Axitinib; Cell Proliferation; Female; Humans; Imidazoles; Indazoles; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Tumor Microenvironment; Vascular Endothelial Growth Factor Receptor-1; Xenograft Model Antitumor Assays	2014
Reversible posterior leukoencephalopathy syndrome induced by axitinib. Clinical genitourinary cancer, 2014, Volume: 12, Issue:1 Topics: Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Middle Aged; Posterior Leukoencephalopathy Syndrome; Protein Kinase Inhibitors; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor	2014
Axitinib dose titration: what's the limiting factor? The Lancet. Oncology, 2013, Volume: 14, Issue:12 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Protein Kinase Inhibitors	2013
Axitinib in advanced renal-cell carcinoma. The Lancet. Oncology, 2013, Volume: 14, Issue:13 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib	2013
Vascular-targeted agents for the treatment of angiosarcoma. Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:2 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Axitinib; Bevacizumab; Cell Death; Cell Differentiation; Cell Line, Tumor; Cell Movement; Doxorubicin; Everolimus; Hemangiosarcoma; Humans; Imidazoles; Indazoles; Neovascularization, Pathologic; Paclitaxel; Protein Array Analysis; Sirolimus; Vascular Endothelial Growth Factor A	2014
Presurgical therapy with axitinib for advanced renal cell carcinoma: a case report. BMC research notes, 2013, Nov-24, Volume: 6 Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Neoplasm Grading; Nephrectomy; Protein Kinase Inhibitors; Radiography; Treatment Outcome	2013
Axitinib affects cell viability and migration of a primary foetal lung adenocarcinoma culture. Cancer investigation, 2014, Volume: 32, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Axitinib; Cell Movement; Cell Survival; Cisplatin; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imidazoles; Indazoles; Lung Neoplasms; Middle Aged; Neoplasm Invasiveness; Protein Kinase Inhibitors; Radiography; RNA, Messenger; Tumor Cells, Cultured; Up-Regulation; Vascular Endothelial Growth Factor A	2014
Axitinib-induced acute pancreatitis: a case report. Anti-cancer drugs, 2014, Volume: 25, Issue:4 Topics: Acute Disease; Adult; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Pancreatitis; Protein Kinase Inhibitors	2014
Axitinib. Prescrire international, 2013, Volume: 22, Issue:143 Topics: Axitinib; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors	2013
Antiangiogenic therapy inhibits venous thrombus resolution. Arteriosclerosis, thrombosis, and vascular biology, 2014, Volume: 34, Issue:3 Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Animals; Axitinib; Blood Coagulation; Capillary Permeability; Collagen; Estradiol; Imidazoles; Indazoles; Macrophages; Male; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Neutrophils; Thrombophilia; Vena Cava, Inferior; Venous Thrombosis	2014
The multikinase inhibitor axitinib is a potent inhibitor of human CYP1A2. Biochemical pharmacology, 2014, Mar-15, Volume: 88, Issue:2 Topics: Adult; Axitinib; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Indazoles; Male; Microsomes, Liver; Middle Aged; Protein Kinase Inhibitors; Protein Structure, Secondary; Young Adult	2014
New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugs. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:4 Topics: Animals; Axitinib; Benzamides; Erlotinib Hydrochloride; Female; HeLa Cells; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lapatinib; Mice; Morpholines; Piperazines; Protein Kinase Inhibitors; Purines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Trypanosomiasis, African	2014
Efficacy of pre-surgical axitinib for shrinkage of inferior vena cava thrombus in a patient with advanced renal cell carcinoma. Japanese journal of clinical oncology, 2014, Volume: 44, Issue:4 Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Hepatic Veins; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Tomography, X-Ray Computed; Treatment Outcome; Vena Cava, Inferior	2014
Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. European urology, 2014, Volume: 66, Issue:3 Topics: Aged; Antineoplastic Agents; Axitinib; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease-Free Survival; Female; Humans; Hypocalcemia; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Pamidronate; Phenylurea Compounds; Prognosis; Pyrroles; Renal Insufficiency; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Zoledronic Acid	2014
Targeting vascular endothelial growth factor receptor signaling in renal cancer: the sooner the better? European urology, 2014, Volume: 66, Issue:5 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Laparoscopy; Male; Neoadjuvant Therapy; Nephrectomy; Protein Kinase Inhibitors	2014
Activity of axitinib in patients with metastatic renal cell carcinoma previously treated with both vascular endothelial growth factor receptor tyrosine-kinase inhibitor and mammalian target of rapamycin inhibitor. International journal of urology : official journal of the Japanese Urological Association, 2014, Volume: 21, Issue:7 Topics: Adolescent; Adult; Aged; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Retrospective Studies; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Young Adult	2014
New affinity probe targeting VEGF receptors for kinase inhibitor selectivity profiling by chemical proteomics. Journal of proteome research, 2014, May-02, Volume: 13, Issue:5 Topics: Amino Acid Sequence; Axitinib; Binding, Competitive; Cell Line, Tumor; Chromatography, Liquid; Female; Humans; Imidazoles; Indazoles; K562 Cells; Models, Chemical; Molecular Docking Simulation; Molecular Sequence Data; Molecular Structure; Placenta; Pregnancy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sequence Homology, Amino Acid; Small Molecule Libraries; Sulfonamides; Tandem Mass Spectrometry	2014
Resistance to the tyrosine kinase inhibitor axitinib is associated with increased glucose metabolism in pancreatic adenocarcinoma. Cell death & disease, 2014, Apr-10, Volume: 5 Topics: Adenocarcinoma; Animals; Axitinib; Cell Membrane; Cell Proliferation; Cell Shape; Cell Survival; Clone Cells; Drug Resistance, Neoplasm; Enzyme Activation; G2 Phase Cell Cycle Checkpoints; Glucose; Glucose Transporter Type 1; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Indazoles; Mice; Mitosis; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt	2014
Kidney cancer: progress and controversies in neoadjuvant therapy. Nature reviews. Urology, 2014, Volume: 11, Issue:5 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Neoadjuvant Therapy; Nephrectomy; Protein Kinase Inhibitors	2014
Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma. Japanese journal of clinical oncology, 2014, Volume: 44, Issue:6 Topics: Administration, Oral; Antineoplastic Agents; Axitinib; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Humans; Imidazoles; Immunohistochemistry; Indazoles; Male; Middle Aged; Molecular Targeted Therapy; Neovascularization, Pathologic; Protein Kinase Inhibitors; Treatment Outcome; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2014
Editorial comment to activity of axitinib in patients with metastatic renal cell carcinoma previously treated with both vascular endothelial growth factor receptor tyrosine-kinase inhibitor and mammalian target of rapamycin inhibitor. International journal of urology : official journal of the Japanese Urological Association, 2014, Volume: 21, Issue:7 Topics: Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2	2014
Axitinib sensitization of high Single Dose Radiotherapy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2014, Volume: 111, Issue:1 Topics: Animals; Apoptosis; Axitinib; Endothelial Cells; Imidazoles; Indazoles; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Protein Kinase Inhibitors; Radiation Tolerance; Radiation-Sensitizing Agents; Radiotherapy Dosage; Receptors, Vascular Endothelial Growth Factor; Sarcoma, Experimental; Signal Transduction	2014
Axitinib alone or in combination with chemotherapeutic drugs exerts potent antitumor activity against human gastric cancer cells in vitro and in vivo. Journal of cancer research and clinical oncology, 2014, Volume: 140, Issue:9 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Axitinib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Cisplatin; Female; Fluorouracil; Humans; Imidazoles; Indazoles; Mice; Mice, Inbred BALB C; Mice, Nude; Stomach Neoplasms; Xenograft Model Antitumor Assays	2014
News products to avoid. Prescrire international, 2014, Volume: 23, Issue:148 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Azacitidine; Decitabine; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Everolimus; Ferrosoferric Oxide; Gefitinib; Hematinics; Humans; Imidazoles; Indazoles; Oxonic Acid; Pyridines; Quinazolines; Risk Assessment; Risk Factors; Sirolimus; Tegafur	2014
Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis. Clinical genitourinary cancer, 2014, Volume: 12, Issue:5 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Cell Differentiation; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome	2014
COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models. Science translational medicine, 2014, Jun-25, Volume: 6, Issue:242 Topics: Angiogenesis Inhibitors; Animals; Axitinib; Carcinogenesis; Cell Line, Tumor; Clone Cells; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Female; Humans; Imidazoles; Indazoles; Liver Neoplasms; Mammary Neoplasms, Experimental; Mice; Neoadjuvant Therapy; Signal Transduction; Survival Analysis; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2014
Vascular endothelial growth factor A improves quality of matured porcine oocytes and developing parthenotes. Domestic animal endocrinology, 2014, Volume: 49 Topics: Animals; Axitinib; Female; Imidazoles; In Vitro Oocyte Maturation Techniques; Indazoles; Oocytes; Parthenogenesis; Protein Kinase Inhibitors; Swine; Vascular Endothelial Growth Factor A	2014
Axitinib augments antitumor activity in renal cell carcinoma via STAT3-dependent reversal of myeloid-derived suppressor cell accumulation. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2014, Volume: 68, Issue:6 Topics: Animals; Axitinib; Carcinoma, Renal Cell; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Female; Imidazoles; Indazoles; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Myeloid Cells; STAT3 Transcription Factor; Xenograft Model Antitumor Assays	2014
Axitinib: VEGF inhibition in advanced thyroid cancer. The Lancet. Oncology, 2014, Volume: 15, Issue:8 Topics: Axitinib; Humans; Imidazoles; Indazoles; Protein Kinase Inhibitors; Thyroid Neoplasms; Vascular Endothelial Growth Factor A	2014
An analysis of seroprevalence and risk factors for parasitic infections of economic importance in small ruminants in Greece. Veterinary journal (London, England : 1997), 2014, Volume: 202, Issue:1 Topics: Adolescent; Adult; Animal Husbandry; Animals; Axitinib; Cross-Sectional Studies; Data Collection; Female; Goat Diseases; Goats; Humans; Imidazoles; Indazoles; Middle Aged; Parasitic Diseases, Animal; Risk Factors; Seroepidemiologic Studies; Sheep; Sheep Diseases; Young Adult	2014
[A case of papillary renal cell carcinoma type 2 resistant to sunitinib responded to second line therapy with axitinib]. Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2014, Volume: 105, Issue:3 Topics: Axitinib; Carcinoma, Papillary; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Imidazoles; Indazoles; Male; Middle Aged; Protein Kinase Inhibitors	2014
Acute myocardial infarction induced by axitinib. Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2014, Volume: 14, Issue:7 Topics: Antineoplastic Agents; Axitinib; Diagnosis, Differential; Humans; Imidazoles; Indazoles; Myocardial Infarction	2014
Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma. Journal of neuro-oncology, 2015, Volume: 121, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Axitinib; Brain Neoplasms; Cell Line, Tumor; Female; Glioblastoma; Humans; Imidazoles; Indazoles; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Neoplastic Stem Cells; Neovascularization, Pathologic; Protein Kinase Inhibitors; Random Allocation; Receptors, Vascular Endothelial Growth Factor; Survival Analysis	2015
In silico discovery of potential VEGFR-2 inhibitors from natural derivatives for anti-angiogenesis therapy. International journal of molecular sciences, 2014, Sep-11, Volume: 15, Issue:9 Topics: Angiogenesis Inhibitors; Axitinib; Binding Sites; Imidazoles; Indazoles; Molecular Docking Simulation; Protein Structure, Tertiary; Quinuclidines; Thermodynamics; Triazoles; Vascular Endothelial Growth Factor Receptor-2	2014
What next? Choosing second-line therapy in progressive renal cell carcinoma. Oncology (Williston Park, N.Y.), 2014, Volume: 28, Issue:9 Topics: Aged; Angiogenesis Inhibitors; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Radiography; Spinal Neoplasms; Sulfonamides	2014
Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries. Molecular imaging, 2014, Volume: 13 Topics: Anilides; Animals; Axitinib; Bone Regeneration; Crizotinib; Fluorine Radioisotopes; Fractures, Bone; Imidazoles; Indazoles; Mice; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Radiopharmaceuticals; Technetium Tc 99m Medronate; Tomography, Emission-Computed, Single-Photon	2014
Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer. BMC cancer, 2014, Oct-02, Volume: 14 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bone Density; Bone Neoplasms; Cell Line, Tumor; Crizotinib; Humans; Imidazoles; Indazoles; Male; Mice, Inbred NOD; Mice, SCID; Prostatic Neoplasms, Castration-Resistant; Pyrazoles; Pyridines; Xenograft Model Antitumor Assays	2014
Topical axitinib suppresses angiogenesis pathways induced by pulsed dye laser. The British journal of dermatology, 2015, Volume: 172, Issue:3 Topics: Administration, Cutaneous; Angiogenesis Inhibitors; Animals; Axitinib; Combined Modality Therapy; Extracellular Signal-Regulated MAP Kinases; Imidazoles; Indazoles; Lasers, Dye; Male; MAP Kinase Signaling System; Neovascularization, Pathologic; Port-Wine Stain; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Rats, Sprague-Dawley; Recurrence; Ribosomal Protein S6 Kinases; RNA, Messenger	2015
Acute aortic dissection in a patient with metastatic renal cell carcinoma treated with axitinib. Acta oncologica (Stockholm, Sweden), 2015, Volume: 54, Issue:4 Topics: Antineoplastic Agents; Aortic Aneurysm, Thoracic; Aortic Dissection; Axitinib; Carcinoma, Renal Cell; ErbB Receptors; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Sunitinib	2015
Chronic inflammation, lymphangiogenesis, and effect of an anti-VEGFR therapy in a mouse model and in human patients with aspiration pneumonia. The Journal of pathology, 2015, Volume: 235, Issue:4 Topics: Animals; Autopsy; Axitinib; Chronic Disease; Cytokines; Disease Models, Animal; Humans; Imidazoles; Indazoles; Inflammation Mediators; Lung; Lymphangiogenesis; Lymphatic Vessels; Male; Mice, Inbred C57BL; Naphthyridines; Pneumonia, Aspiration; Protein Kinase Inhibitors; Time Factors; Vascular Endothelial Growth Factor C; Vascular Endothelial Growth Factor Receptor-3	2015
Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Molecular cancer therapeutics, 2015, Volume: 14, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Mice; Mice, SCID; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2015
Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US. Journal of medical economics, 2015, Volume: 18, Issue:3 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Everolimus; Health Expenditures; Health Services; Humans; Imidazoles; Indazoles; Indoles; Markov Chains; Models, Econometric; Pyrroles; Quality-Adjusted Life Years; Sunitinib; United States	2015
Non-significant impact of proteinuria on renal function in Japanese patients with metastatic renal cell carcinoma treated with axitinib. International journal of clinical oncology, 2015, Volume: 20, Issue:4 Topics: Aged; Antineoplastic Agents; Asian People; Axitinib; Carcinoma, Renal Cell; Female; Glomerular Filtration Rate; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proteinuria; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies	2015
Treatment of newborn mice with inhibitors of vascular endothelial growth factor receptor tyrosine kinase induces abnormal retinal vascular patterning. Biological & pharmaceutical bulletin, 2014, Volume: 37, Issue:12 Topics: Animals; Animals, Newborn; Axitinib; Gene Expression Regulation, Developmental; Gene Expression Regulation, Enzymologic; Imidazoles; Indazoles; Mice; Mice, Inbred ICR; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Retinal Vessels	2014
Interactions of multitargeted kinase inhibitors and nucleoside drugs: Achilles heel of combination therapy? Molecular cancer therapeutics, 2015, Volume: 14, Issue:1 Topics: Axitinib; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Nucleoside Transport Proteins; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib	2015
Heparan sulfate D-glucosaminyl 3-O-sulfotransferase-3B1 (HS3ST3B1) promotes angiogenesis and proliferation by induction of VEGF in acute myeloid leukemia cells. Journal of cellular biochemistry, 2015, Volume: 116, Issue:6 Topics: Axitinib; Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Indazoles; Leukemia, Myeloid, Acute; Neovascularization, Pathologic; Sulfotransferases; Vascular Endothelial Growth Factor A	2015
Ocular drug delivery nanowafer with enhanced therapeutic efficacy. ACS nano, 2015, Feb-24, Volume: 9, Issue:2 Topics: Animals; Axitinib; Cornea; Corneal Neovascularization; Diffusion; Drug Delivery Systems; Drug Liberation; Eye; Female; Imidazoles; Indazoles; Mice; Mice, Inbred C57BL; Nanotechnology; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Wound Healing	2015
[Presurgical treatment of axitinib reduced operation risk by downsizing the vena cava tumor thrombus in advanced renal cell carcinomas: two case reports]. Hinyokika kiyo. Acta urologica Japonica, 2014, Volume: 60, Issue:12 Topics: Aged; Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Preoperative Care; Protein Kinase Inhibitors; Vena Cava, Inferior	2014
In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells. Neuro-oncology, 2015, Volume: 17, Issue:8 Topics: Antineoplastic Agents; Axitinib; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Glioblastoma; Humans; Imidazoles; In Vitro Techniques; Indazoles; Myxoma virus; Neoplastic Stem Cells; Oncolytic Virotherapy; Oncolytic Viruses; Small Molecule Libraries	2015
Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy. Cancer letters, 2015, Apr-10, Volume: 359, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Papillary; Class I Phosphatidylinositol 3-Kinases; DNA Copy Number Variations; DNA Mutational Analysis; Drug Screening Assays, Antitumor; Female; Gene Amplification; Genetic Association Studies; Humans; Imidazoles; Indazoles; Iodine Radioisotopes; Male; Middle Aged; Phosphatidylinositol 3-Kinases; Polymorphism, Single Nucleotide; Radiation Tolerance; Radiopharmaceuticals; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3	2015
Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Nature, 2015, Mar-05, Volume: 519, Issue:7541 Topics: Angiogenesis Inhibitors; Axitinib; Cell Line; Cell Proliferation; Crystallization; Crystallography, X-Ray; Drug Repositioning; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Molecular Conformation; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Vascular Endothelial Growth Factor Receptor-2	2015
Kidney cancer, version 3.2015. Journal of the National Comprehensive Cancer Network : JNCCN, 2015, Volume: 13, Issue:2 Topics: Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides	2015
NICE guidance on axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment. The Lancet. Oncology, 2015, Volume: 16, Issue:4 Topics: Axitinib; Carcinoma, Renal Cell; Guidelines as Topic; Humans; Imidazoles; Indazoles	2015
Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy. Scientific reports, 2015, Mar-11, Volume: 5 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Axitinib; Cell Line, Tumor; Chick Embryo; Combined Modality Therapy; Cymenes; Disease Models, Animal; Doxorubicin; Drug Synergism; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Organometallic Compounds; Oxygen Consumption; Photochemotherapy; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Tumor Burden	2015
Professor Shukui Qin: patient reported outcomes in study of axitinib or sorafenib in Asian patients with metastatic renal cell carcinoma. Chinese clinical oncology, 2015, Volume: 4, Issue:1 Topics: Asia; Asian People; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Time Factors; Treatment Outcome	2015
Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan. BMC urology, 2015, Apr-16, Volume: 15 Topics: Aged; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome	2015
Cost-effectiveness analysis of axitinib through a probabilistic decision model. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:8 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Markov Chains; Models, Economic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Sorafenib; Uncertainty	2015
Involvement of corneal lymphangiogenesis in a mouse model of allergic eye disease. Investigative ophthalmology & visual science, 2015, Volume: 56, Issue:5 Topics: Animals; Axitinib; Cornea; Disease Models, Animal; Female; Glycoproteins; Imidazoles; Immunoglobulin E; Indazoles; Keratoconjunctivitis; Lymphangiogenesis; Lymphatic Vessels; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Microscopy, Confocal; Ovalbumin; Protein Kinase Inhibitors; Real-Time Polymerase Chain Reaction; Vascular Endothelial Growth Factor C; Vascular Endothelial Growth Factor D; Vascular Endothelial Growth Factor Receptor-3	2015
The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function. PloS one, 2015, Volume: 10, Issue:6 Topics: Apoptosis; Axitinib; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Cytokines; Dendritic Cells; Dose-Response Relationship, Drug; Down-Regulation; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Lymphocyte Activation; Monocytes; p38 Mitogen-Activated Protein Kinases; Phenotype; Phosphorylation; Proto-Oncogene Proteins c-rel; STAT3 Transcription Factor; T-Lymphocytes; Vascular Endothelial Growth Factor A	2015
Prolonging survival in metastatic renal cell carcinoma patients treated with targeted anticancer agents: a single-center experience of treatment strategy modifications. The Canadian journal of urology, 2015, Volume: 22, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Life Style; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Patient Education as Topic; Phenylurea Compounds; Pyrroles; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate	2015
Taxonomic revision of Drymoluber Amaral, 1930 (Serpentes: Colubridae). Zootaxa, 2013, Volume: 3716 Topics: Animal Distribution; Animals; Axitinib; Brazil; Colubridae; Female; Imidazoles; Indazoles; Male; Principal Component Analysis; Sex Factors; Species Specificity	2013
Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation. Journal of hematology & oncology, 2015, Aug-04, Volume: 8 Topics: Axitinib; Fusion Proteins, bcr-abl; Humans; Imidazoles; Indazoles; Point Mutation; Protein Kinase Inhibitors	2015
Successful Control of Carcinoma of Unknown Primary with Axitinib, a Novel Molecular-Targeted Agent: A Case Report. Chemotherapy, 2014, Volume: 60, Issue:5-6 Topics: Axitinib; Bone Neoplasms; Drug Delivery Systems; Humans; Imidazoles; Indazoles; Male; Middle Aged; Neoplasms, Unknown Primary; Treatment Outcome	2014
Sequential molecularly targeted drug therapy including axitinib for a patient with end-stage renal failure and metastatic renal cell carcinoma. Hemodialysis international. International Symposium on Home Hemodialysis, 2016, Volume: 20, Issue:2 Topics: Antineoplastic Agents; Axitinib; Disease-Free Survival; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Renal Dialysis; Renal Insufficiency, Chronic	2016
Diarrhea With Clostridium difficile-Positive Stool-Trick or Treat: A Teachable Moment. JAMA internal medicine, 2015, Volume: 175, Issue:11 Topics: Aged; Anti-Bacterial Agents; Axitinib; Carcinoma, Renal Cell; Clostridioides difficile; Costs and Cost Analysis; Diagnosis, Differential; Diarrhea; Enterocolitis, Pseudomembranous; Feces; Female; Humans; Imidazoles; Indazoles; Metronidazole; Protein Kinase Inhibitors; Recurrence; Treatment Outcome; Vancomycin; Withholding Treatment	2015
Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma. Clinical genitourinary cancer, 2016, Volume: 14, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib	2016
Spheroid-plug model as a tool to study tumor development, angiogenesis, and heterogeneity in vivo. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:2 Topics: Animals; Antineoplastic Agents; Axitinib; Biomarkers, Tumor; Carcinogenesis; Cell Proliferation; Cell Survival; Collagen; Drug Combinations; Endothelial Cells; Hematopoietic Stem Cells; Imidazoles; Indazoles; Injections, Subcutaneous; Laminin; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplastic Stem Cells; Neovascularization, Pathologic; Proteoglycans; Receptors, CXCR4; Spheroids, Cellular; Tumor Cells, Cultured	2016
VEGF and LPS synergistically silence inflammatory response to Plasmodium berghei infection and protect against cerebral malaria. Pathogens and global health, 2015, Volume: 109, Issue:6 Topics: Acute-Phase Proteins; Animals; Axitinib; Carrier Proteins; Disease Models, Animal; Drug Synergism; Imidazoles; Immune Tolerance; Indazoles; Lipopolysaccharides; Malaria, Cerebral; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Parasitemia; Plasmodium berghei; Protein Kinase Inhibitors; T-Lymphocytes, Regulatory; Vascular Endothelial Growth Factor A	2015
Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib. Targeted oncology, 2016, Volume: 11, Issue:2 Topics: Axitinib; Carcinoma, Renal Cell; Case-Control Studies; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Imidazoles; Indazoles; Kidney; Kidney Neoplasms; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic	2016
Retinal region-dependent susceptibility of capillaries to high-concentration oxygen exposure and vascular endothelial growth factor receptor inhibition in neonatal mice. Journal of pharmacological sciences, 2015, Volume: 129, Issue:2 Topics: Amlodipine; Animals; Animals, Newborn; Axitinib; Calcium Channel Blockers; Capillaries; Female; Hyperoxia; Imidazoles; Indazoles; Male; Mice, Inbred ICR; Nicardipine; Oxygen; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Retinal Artery; Time Factors; Vasoconstriction	2015
A streamlined search technology for identification of synergistic drug combinations. Scientific reports, 2015, Sep-29, Volume: 5 Topics: Antineoplastic Agents; Axitinib; Benzamides; Cell Line, Tumor; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Drug Combinations; Drug Screening Assays, Antitumor; Drug Synergism; Epithelial Cells; Erlotinib Hydrochloride; Humans; Imidazoles; Indazoles; Kidney; Piperazines; Pyrazoles	2015
Pharmacological targeting of VEGFR signaling with axitinib inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosis. American journal of physiology. Lung cellular and molecular physiology, 2015, Dec-15, Volume: 309, Issue:12 Topics: Animals; Axitinib; Cell Line, Tumor; Cell Proliferation; Chemokine CCL2; Disease Models, Animal; Female; Imidazoles; Indazoles; Lung; Lung Diseases; Lung Neoplasms; Lymphangioleiomyomatosis; Mice; Mice, Inbred C57BL; Mice, Nude; Nitric Oxide Synthase Type II; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins; Up-Regulation; Vascular Endothelial Growth Factor D	2015
Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cells. Oncotarget, 2015, Nov-03, Volume: 6, Issue:34 Topics: Apoptosis; Axitinib; Carcinoma, Renal Cell; Cell Line, Tumor; Cellular Senescence; DNA Damage; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Killer Cells, Natural; Mitosis; Protein Kinase Inhibitors	2015
Geographical tongue induced by axitinib. BMJ case reports, 2015, Oct-16, Volume: 2015 Topics: Axitinib; Glossitis, Benign Migratory; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors	2015
Short-term treatment with VEGF receptor inhibitors induces retinopathy of prematurity-like abnormal vascular growth in neonatal rats. Experimental eye research, 2016, Volume: 143 Topics: Animals; Animals, Newborn; Axitinib; Disease Models, Animal; Female; Fluorescent Antibody Technique, Indirect; Imidazoles; Indazoles; Microscopy, Fluorescence; Phenylurea Compounds; Pregnancy; Protein-Tyrosine Kinases; Quinazolines; Rats; Rats, Sprague-Dawley; Retinal Neovascularization; Retinal Vessels; Retinopathy of Prematurity; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2016
Cutaneous Vasculopathy as an Adverse Effect of the Anti-Vascular Endothelial Growth Factor Agent Axitinib. JAMA dermatology, 2016, Volume: 152, Issue:2 Topics: Axitinib; Humans; Imidazoles; Indazoles; Male; Middle Aged; Protein Kinase Inhibitors; Skin Diseases, Vascular; Vascular Endothelial Growth Factor A	2016
Novel TKI-resistant BCR-ABL1 gatekeeper residue mutations retain in vitro sensitivity to axitinib. Leukemia, 2016, Volume: 30, Issue:6 Topics: Axitinib; Dasatinib; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Humans; Imidazoles; In Vitro Techniques; Indazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridazines	2016
In Vitro Kinetic Characterization of Axitinib Metabolism. Drug metabolism and disposition: the biological fate of chemicals, 2016, Volume: 44, Issue:1 Topics: Angiogenesis Inhibitors; Axitinib; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Female; Genotype; Glucuronides; Glucuronosyltransferase; Humans; Imidazoles; Inactivation, Metabolic; Indazoles; Kinetics; Male; Metabolic Clearance Rate; Microsomes, Liver; Models, Biological; Oxidation-Reduction; Phenotype; Protein Kinase Inhibitors; Recombinant Proteins; Substrate Specificity; Sulfoxides	2016
Murine colitis treated with multitargeted tyrosine kinase inhibitors. The Journal of surgical research, 2016, Volume: 200, Issue:2 Topics: Animals; Axitinib; Colitis; Imidazoles; Indazoles; Indoles; Male; Mice; Mice, Inbred C57BL; Microvessels; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome	2016
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcin Cancer, 2016, Feb-01, Volume: 122, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Databases, Factual; Diarrhea; Drug Administration Schedule; Fatigue; Female; Hand-Foot Syndrome; Humans; Imidazoles; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Models, Statistical; Molecular Targeted Therapy; Mucositis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A	2016
Long-term survival following multidisciplinary treatment of metastatic sarcomatoid renal cell carcinoma: a case report. Journal of medical case reports, 2015, Nov-19, Volume: 9 Topics: Antineoplastic Agents; Axitinib; Biopsy; Bone Neoplasms; Carcinoma, Renal Cell; Combined Modality Therapy; Everolimus; Female; Humans; Imidazoles; Indazoles; Interferon-alpha; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quality of Life; Radiotherapy; Survivors; Tomography, X-Ray Computed	2015
Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia. Leukemia, 2016, Volume: 30, Issue:6 Topics: Axitinib; Fusion Proteins, bcr-abl; Humans; Imidazoles; Indazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Protein Kinase Inhibitors	2016
Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2016, Volume: 18, Issue:9 Topics: Animals; Antineoplastic Agents; Axitinib; Blotting, Western; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Humans; Imidazoles; Immunohistochemistry; Indazoles; Indoles; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays	2016
Successful treatment with an anti-PD-1 antibody for progressing brain metastases in renal cell cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:3 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Brain Edema; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Lung Neoplasms; Middle Aged; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrimidines; Radiation Injuries; Sulfonamides	2016
Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US. Journal of medical economics, 2016, Volume: 19, Issue:5 Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Comorbidity; Disease-Free Survival; Dose-Response Relationship, Drug; Everolimus; Fees, Pharmaceutical; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib	2016
Axitinib-induced proteinuria and efficacy in patients with metastatic renal cell carcinoma. International journal of clinical oncology, 2016, Volume: 21, Issue:4 Topics: Adult; Aged; Angiogenesis Inhibitors; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proteinuria; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome	2016
Tyrosine kinase inhibitors target cancer stem cells in renal cell cancer. Oncology reports, 2016, Volume: 35, Issue:3 Topics: Axitinib; Carcinoma, Renal Cell; Cell Communication; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Indazoles; Indoles; Neoplastic Stem Cells; Niacinamide; Oxygen; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Tumor Microenvironment	2016
A Case of Pancreatic Side Effects Resulting from Sorafenib and Axitinib Treatment of Stage IV Renal Cell Carcinoma. The Keio journal of medicine, 2015, Volume: 64, Issue:4 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Pancreatitis; Phenylurea Compounds; Sorafenib	2015
Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review. Current medical research and opinion, 2016, Volume: 32, Issue:4 Topics: Aged; Animals; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Everolimus; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome; United States	2016
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Metastatic Renal Cell Carcinoma (mRCC). Annals of the Academy of Medicine, Singapore, 2015, Volume: 44, Issue:10 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Singapore; Sirolimus; Sorafenib; Sulfonamides; Sunitinib	2015
Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells. Cell communication and signaling : CCS, 2016, Feb-24, Volume: 14 Topics: Adaptor Proteins, Signal Transducing; Axitinib; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imidazoles; Indazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Niacinamide; Phenylurea Compounds; Point Mutation; Protein Interaction Maps; Protein Kinase Inhibitors; Sorafenib; src-Family Kinases	2016
Axitinib inhibits retinal and choroidal neovascularization in in vitro and in vivo models. Experimental eye research, 2016, Volume: 145 Topics: Aged; Animals; Axitinib; Cell Proliferation; Choroidal Neovascularization; Disease Models, Animal; Endothelial Cells; Fluorescein Angiography; Humans; Imidazoles; Immunohistochemistry; Indazoles; Intravitreal Injections; Male; Mesenchymal Stem Cells; Pericytes; Protein Kinase Inhibitors; Rats	2016
Response to post-axitinib treatment in patients with metastatic renal cell carcinoma. BMC cancer, 2016, Mar-29, Volume: 16 Topics: Adult; Aged; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Male; Middle Aged; Pyrroles; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2016
Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling. Cell reports, 2016, 05-10, Volume: 15, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Axitinib; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glucose; Glutamine; Glycolysis; Humans; Imidazoles; Indazoles; Indoles; Intestinal Neoplasms; Lactic Acid; Membrane Transport Proteins; Mice; Models, Biological; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Signal Transduction; Sirolimus; Stomach Neoplasms; Sunitinib; TOR Serine-Threonine Kinases; Up-Regulation	2016
Dual-pH responsive micelle platform for co-delivery of axitinib and doxorubicin. International journal of pharmaceutics, 2016, Jun-30, Volume: 507, Issue:1-2 Topics: Angiogenesis Inhibitors; Axitinib; Cell Survival; Cells, Cultured; Doxorubicin; Drug Delivery Systems; Drug Liberation; Humans; Hydrogen-Ion Concentration; Imidazoles; Indazoles; Micelles; Polymers; Xenograft Model Antitumor Assays	2016
Vascular endothelial growth factor partially induces pruritus via epidermal hyperinnervation in imiquimod-induced psoriasiform dermatitis in mice. Journal of dermatological science, 2016, Volume: 83, Issue:2 Topics: Aminoquinolines; Animals; Axitinib; Dermatitis, Atopic; Disease Models, Animal; Epidermis; Humans; Imidazoles; Imiquimod; Indazoles; Mice; Pruritus; Psoriasis; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A	2016
PEGylated lipid bilayer-supported mesoporous silica nanoparticle composite for synergistic co-delivery of axitinib and celastrol in multi-targeted cancer therapy. Acta biomaterialia, 2016, 07-15, Volume: 39 Topics: Animals; Axitinib; Cell Line, Tumor; Drug Delivery Systems; Drug Screening Assays, Antitumor; Female; Imidazoles; Indazoles; Lipid Bilayers; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms, Experimental; Pentacyclic Triterpenes; Porosity; Silicon Dioxide; Triterpenes	2016
Real-World Axitinib Use in the United States: A Retrospective Study Using Linked Datasets. Journal of managed care & specialty pharmacy, 2016, Volume: 22, Issue:6 Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Cohort Studies; Databases, Factual; Female; Humans; Imidazoles; Indazoles; Insurance Claim Review; Kidney Neoplasms; Male; Middle Aged; Pharmacy; Retrospective Studies; United States	2016
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma. European urology, 2016, Volume: 70, Issue:6 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Remission Induction; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Tumor Burden	2016
Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma. Oncotarget, 2016, Jul-05, Volume: 7, Issue:27 Topics: Activin Receptors, Type II; Animals; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Immunoglobulin Fc Fragments; Indazoles; Indoles; Kidney Neoplasms; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sunitinib; Tumor Burden; Xenograft Model Antitumor Assays	2016
CT spectral imaging for monitoring the therapeutic efficacy of VEGF receptor kinase inhibitor AG-013736 in rabbit VX2 liver tumours. European radiology, 2017, Volume: 27, Issue:3 Topics: Animals; Axitinib; Disease Models, Animal; Imidazoles; Indazoles; Liver; Liver Neoplasms, Experimental; Male; Protein Kinase Inhibitors; Rabbits; Receptors, Vascular Endothelial Growth Factor; Reproducibility of Results; Tomography, X-Ray Computed; Treatment Outcome	2017
Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma. Cancer medicine, 2016, Volume: 5, Issue:8 Topics: Adult; Aged; Antineoplastic Agents; Axitinib; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Renal Cell; CD28 Antigens; Chemotherapy, Adjuvant; Female; Humans; Imidazoles; Indazoles; Indoles; Kaplan-Meier Estimate; Karnofsky Performance Status; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Proteins; Nephrectomy; Preoperative Period; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome; V-Set Domain-Containing T-Cell Activation Inhibitor 1; Vascular Endothelial Growth Factor A; Young Adult	2016
Tumor Thrombus of Renal Cell Carcinoma Extending Into the Inferior Vena Cava, Ovarian Vein, and Ureter Treated With Neoadjuvant Axitinib. Urology, 2016, Volume: 95 Topics: Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Middle Aged; Neoplasm Invasiveness; Neoplastic Cells, Circulating; Ovary; Ureteral Neoplasms; Veins; Vena Cava, Inferior	2016
Binding of an anticancer drug, axitinib to human serum albumin: Fluorescence quenching and molecular docking study. Journal of photochemistry and photobiology. B, Biology, 2016, Volume: 162 Topics: Antineoplastic Agents; Axitinib; Binding Sites; Humans; Imidazoles; Indazoles; Molecular Docking Simulation; Protein Binding; Protein Conformation; Serum Albumin; Spectrometry, Fluorescence	2016
Efficacy and safety of axitinib in elderly patients with metastatic renal cell carcinoma. Medical oncology (Northwood, London, England), 2016, Volume: 33, Issue:8 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quality of Life; Retrospective Studies; Treatment Outcome	2016
Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline. Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:3 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Logistic Models; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib; Time Factors	2016
Assessment of Efficacy, Safety, and Quality of Life of 124 Patients Treated With Axitinib as Second-Line Therapy for Metastatic Renal-Cell Carcinoma: Experience in Real-World Clinical Practice in Japan. Clinical genitourinary cancer, 2017, Volume: 15, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Japan; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quality of Life; Retrospective Studies; Survival Analysis; Treatment Outcome	2017
Axitinib blocks Wnt/β-catenin signaling and directs asymmetric cell division in cancer. Proceedings of the National Academy of Sciences of the United States of America, 2016, 08-16, Volume: 113, Issue:33 Topics: Animals; Axitinib; beta Catenin; Cell Division; DNA Helicases; Glycogen Synthase Kinase 3 beta; HCT116 Cells; Humans; Imidazoles; Indazoles; Male; Mice; Mice, Inbred C57BL; Neoplasms; Protein Kinase Inhibitors; Regeneration; Ubiquitin-Protein Ligases; Wnt Signaling Pathway; Zebrafish	2016
Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithms. World journal of urology, 2017, Volume: 35, Issue:4 Topics: Algorithms; Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Consensus; Decision Support Techniques; Decision Trees; Everolimus; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Nivolumab; Protein Kinase Inhibitors; Pyridines; Treatment Failure	2017
Two anti-angiogenic TKI-PET tracers, [(11)C]axitinib and [(11)C]nintedanib: Radiosynthesis, in vivo metabolism and initial biodistribution studies in rodents. Nuclear medicine and biology, 2016, Volume: 43, Issue:10 Topics: Angiogenesis Inhibitors; Animals; Axitinib; Carbon Radioisotopes; Cell Line, Tumor; Cell Transformation, Neoplastic; Humans; Imidazoles; Indazoles; Indoles; Mice; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Radioactive Tracers; Radiochemistry; Rats; Tissue Distribution	2016
Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib. Oncotarget, 2016, Jun-21, Volume: 7, Issue:25 Topics: Angiogenesis Inhibitors; Animals; Axitinib; Carcinoma, Renal Cell; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Pyrroles; Random Allocation; Sunitinib; Xenograft Model Antitumor Assays	2016
Association of axitinib plasma exposure and genetic polymorphisms of ABC transporters with axitinib-induced toxicities in patients with renal cell carcinoma. Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:4 Topics: Adult; Aged; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Axitinib; Carcinoma, Renal Cell; Female; Genotype; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Proteins; Polymorphism, Genetic; Protein Kinase Inhibitors; Retrospective Studies; Treatment Failure	2016
[Complete response to tyrosine kinase inhibitors in metastatic renal cancer. Report of four cases]. Archivos espanoles de urologia, 2016, Volume: 69, Issue:7 Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Remission Induction; Sunitinib	2016
Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma. Clinical genitourinary cancer, 2017, Volume: 15, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; Tumor Burden	2017
[Metastatic Renal Cell Carcinoma in Paranasal Sinus for which Periodic Drug Withdrawal Schedule of Axitinib was Effective : A Case Report]. Hinyokika kiyo. Acta urologica Japonica, 2016, Volume: 62, Issue:9 Topics: Axitinib; Carcinoma, Renal Cell; Imidazoles; Indazoles; Kidney Neoplasms; Nephrectomy; Nose Neoplasms; Protein Kinase Inhibitors; Tomography, X-Ray Computed; Treatment Outcome	2016
Lack of effect of smoking status on axitinib pharmacokinetics in patients with non-small-cell lung cancer. Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Axitinib; Carcinoma, Non-Small-Cell Lung; Female; Humans; Imidazoles; Indazoles; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Protein Kinase Inhibitors; Smoking	2016
Supratherapeutic INR resulting from the initiation of warfarin in a patient receiving axitinib. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2018, Volume: 24, Issue:1 Topics: Aged; Angiogenesis Inhibitors; Anticoagulants; Axitinib; Binding, Competitive; Drug Interactions; Humans; Imidazoles; Indazoles; International Normalized Ratio; Male; Protein Binding; Warfarin	2018
Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Axitinib; Dideoxynucleosides; Drug Administration Schedule; Female; Humans; Imidazoles; Indazoles; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Vascular Endothelial Growth Factor A	2016
[A Case of Renal Cell Carcinoma with Malignant Pleural Effusion Showing Marked Response to Axitinib]. Hinyokika kiyo. Acta urologica Japonica, 2016, Volume: 62, Issue:10 Topics: Adult; Axitinib; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Nephrectomy; Pleural Effusion, Malignant; Protein Kinase Inhibitors; Tomography, X-Ray Computed	2016
Dual inhibition using cabozantinib overcomes HGF/MET signaling mediated resistance to pan-VEGFR inhibition in orthotopic and metastatic neuroblastoma tumors. International journal of oncology, 2017, Volume: 50, Issue:1 Topics: Anilides; Animals; Apoptosis; Axitinib; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Hepatocyte Growth Factor; Humans; Imidazoles; Indazoles; Mice; Neoplasm Invasiveness; Neuroblastoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyridines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Xenograft Model Antitumor Assays	2017
Axitinib induces senescence-associated cell death and necrosis in glioma cell lines: The proteasome inhibitor, bortezomib, potentiates axitinib-induced cytotoxicity in a p21(Waf/Cip1) dependent manner. Oncotarget, 2017, Jan-10, Volume: 8, Issue:2 Topics: Axitinib; Bortezomib; Cell Death; Cell Line, Tumor; Cell Survival; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; G2 Phase Cell Cycle Checkpoints; Gene Expression; Glioma; Humans; Imidazoles; Indazoles; Mitosis; Necrosis; Proteasome Inhibitors; Protein Kinase Inhibitors; Reactive Oxygen Species; Signal Transduction	2017
Antiangiogenic and Toxic Effects of Genistein, Usnic Acid, and Their Copper Complexes in Zebrafish Embryos at Different Developmental Stages. Chemistry & biodiversity, 2017, Volume: 14, Issue:3 Topics: Angiogenesis Inhibitors; Animals; Axitinib; Benzofurans; Cell Line, Tumor; Cell Movement; Cell Survival; Coordination Complexes; Copper; Embryo, Nonmammalian; Embryonic Development; Genistein; Humans; Imidazoles; Indazoles; Matrix Metalloproteinases; Microscopy, Fluorescence; Neovascularization, Physiologic; Zebrafish	2017
Folate-Hapten-Mediated Immunotherapy Synergizes with Vascular Endothelial Growth Factor Receptor Inhibitors in Treating Murine Models of Cancer. Molecular cancer therapeutics, 2017, Volume: 16, Issue:3 Topics: Animals; Antineoplastic Agents; Axitinib; Cell Line, Tumor; Combined Modality Therapy; Disease Models, Animal; Female; Folic Acid; Haptens; Humans; Imidazoles; Immunotherapy; Indazoles; Mice; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; T-Lymphocyte Subsets; Tumor Burden; Xenograft Model Antitumor Assays	2017
Pituitary Metastasis from Renal Cell Carcinoma: Description of a Case Report. The American journal of case reports, 2017, Jan-03, Volume: 18 Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Disease Progression; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Neurosurgical Procedures; Niacinamide; Phenylurea Compounds; Pituitary Neoplasms; Pyrroles; Radiotherapy, Adjuvant; Sorafenib; Sunitinib; Treatment Outcome	2017
Visualization and Quantification of Browning Using a Ucp1-2A-Luciferase Knock-in Mouse Model. Diabetes, 2017, Volume: 66, Issue:2 Topics: Adipocytes, Beige; Adipocytes, Brown; Animals; Axitinib; Blotting, Western; Ear; Gene Knock-In Techniques; Glucose Tolerance Test; Imidazoles; Immunohistochemistry; In Vitro Techniques; Indazoles; Luciferases; Luminescent Measurements; Male; Mice; Models, Animal; Oxygen Consumption; Protein Kinase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Subcutaneous Fat; Thermogenesis; Uncoupling Protein 1	2017
Combined VEGF and PDGF inhibition for neovascular AMD: anti-angiogenic properties of axitinib on human endothelial cells and pericytes in vitro. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2017, Volume: 255, Issue:5 Topics: Axitinib; Cell Proliferation; Cell Survival; Cells, Cultured; Choroidal Neovascularization; Endothelium, Vascular; Humans; Imidazoles; Indazoles; Macular Degeneration; Pericytes; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Signal Transduction; Vascular Endothelial Growth Factor A	2017
[A Case of Hydrocephalus Due to Brain Metastasis from Renal Cell Carcinoma Successfully Treated with Axitinib]. Hinyokika kiyo. Acta urologica Japonica, 2017, Volume: 63, Issue:1 Topics: Aged; Axitinib; Brain Neoplasms; Carcinoma, Renal Cell; Humans; Hydrocephalus; Imidazoles; Indazoles; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Multimodal Imaging; Nephrectomy; Protein Kinase Inhibitors; Tomography, X-Ray Computed	2017
Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA. International journal of urology : official journal of the Japanese Urological Association, 2017, Volume: 24, Issue:4 Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Nephrectomy; Practice Guidelines as Topic; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome	2017
CLARITY reveals dynamics of ovarian follicular architecture and vasculature in three-dimensions. Scientific reports, 2017, 03-23, Volume: 7 Topics: Animals; Axitinib; Corpus Luteum; Female; Fluorescent Antibody Technique; Imaging, Three-Dimensional; Imidazoles; Indazoles; Mice; Microvessels; Mutation; Ovarian Follicle; Ovary; Promoter Regions, Genetic; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A	2017
Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma. Targeted oncology, 2017, Volume: 12, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Receptor, Platelet-Derived Growth Factor beta; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Survival Analysis; Tumor Burden; Young Adult	2017
Hemodialysis does not impact axitinib exposure: clinical case of a patient with metastatic renal cell carcinoma. Cancer chemotherapy and pharmacology, 2017, Volume: 79, Issue:6 Topics: Angiogenesis Inhibitors; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Membranes, Artificial; Middle Aged; Protein Kinase Inhibitors; Renal Dialysis; Treatment Outcome	2017
Computational analysis of ABL kinase mutations allows predicting drug sensitivity against selective kinase inhibitors. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2017, Volume: 39, Issue:5 Topics: Axitinib; Computational Biology; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Docking Simulation; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl	2017
Axitinib in metastatic renal cell carcinoma: patient characteristics and treatment patterns in US community oncology centers. Future oncology (London, England), 2017, Volume: 13, Issue:15 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Community Health Centers; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Medical Oncology; Middle Aged; Retrospective Studies; Time Factors; Treatment Outcome; United States	2017
Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre. European journal of cancer (Oxford, England : 1990), 2017, Volume: 79 Topics: Age Factors; Age of Onset; Antineoplastic Agents; Axitinib; Cancer Care Facilities; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Protein Kinase Inhibitors; Treatment Outcome	2017
Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study. BMC cancer, 2017, 05-22, Volume: 17, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Female; Hemoglobins; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Polycythemia; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; Young Adult	2017
Insulin-like growth factor-1 signaling is responsible for cathepsin G-induced aggregation of breast cancer MCF-7 cells. Cancer science, 2017, Volume: 108, Issue:8 Topics: Autocrine Communication; Axitinib; Breast Neoplasms; Cathepsin G; Cell Aggregation; Female; Humans; Imidazoles; Indazoles; Indoles; Insulin-Like Growth Factor I; MCF-7 Cells; Phosphorylation; Pyrazines; Pyrroles; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Small Molecule Libraries; Sunitinib	2017
Value-Based pricing and the end of pharmaceutical pricing as we know it? A case study on sorafenib and axitinib. Pharmacological research, 2017, Volume: 124 Topics: Axitinib; Humans; Imidazoles; Indazoles; Niacinamide; Pharmaceutical Preparations; Phenylurea Compounds; Sorafenib	2017
Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. Clinical genitourinary cancer, 2017, Volume: 15, Issue:6 Topics: Aged; Axitinib; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Interactions; Female; Gastrointestinal Diseases; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proton Pump Inhibitors; Pyrroles; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome	2017
Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC). European journal of endocrinology, 2017, Volume: 177, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Axitinib; Carcinoma, Neuroendocrine; Female; Humans; Imidazoles; Indazoles; Iodine Radioisotopes; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Retrospective Studies; Spain; Thyroid Neoplasms; Treatment Outcome	2017
Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database. Current medical research and opinion, 2017, Volume: 33, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Cohort Studies; Databases, Factual; Disease-Free Survival; Everolimus; Female; France; Humans; Imidazoles; Indazoles; Indoles; Insurance, Health; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib	2017
The opening/closure of the P-loop and hinge of BCR-ABL1 decodes the low/high bioactivities of dasatinib and axitinib. Physical chemistry chemical physics : PCCP, 2017, Aug-23, Volume: 19, Issue:33 Topics: Axitinib; Dasatinib; Fusion Proteins, bcr-abl; Hydrogen Bonding; Imidazoles; Indazoles; Molecular Dynamics Simulation; Principal Component Analysis; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Thermodynamics	2017
Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy. Clinical genitourinary cancer, 2017, Volume: 15, Issue:6 Topics: Adult; Aged; Axitinib; Carcinoma, Renal Cell; Everolimus; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Survival Analysis; Treatment Outcome	2017
Axitinib-related osteonecrosis of the jaw. Oral surgery, oral medicine, oral pathology and oral radiology, 2017, Volume: 124, Issue:5 Topics: Aged; Axitinib; Carcinoma, Renal Cell; Conservative Treatment; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Maxillary Diseases; Osteonecrosis; Protein Kinase Inhibitors; Radiography, Panoramic	2017
Baseline risk stratification or duration of prior therapy predicts prognosis in patients with metastatic renal cell carcinoma treated with axitinib. Japanese journal of clinical oncology, 2017, Dec-01, Volume: 47, Issue:12 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Japan; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Risk Assessment; Treatment Outcome; Young Adult	2017
Circulating Cell-Free DNA Levels in Patients with Metastatic Renal Cell Carcinoma. Oncology research and treatment, 2017, Volume: 40, Issue:11 Topics: Aged; Aged, 80 and over; Axitinib; Carcinoma, Renal Cell; Cell-Free Nucleic Acids; Combined Modality Therapy; Disease-Free Survival; Everolimus; Female; Follow-Up Studies; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Predictive Value of Tests; Prospective Studies; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib	2017
Axitinib attenuates intraplaque angiogenesis, haemorrhages and plaque destabilization in mice. Vascular pharmacology, 2018, Volume: 100 Topics: Animals; Arteries; Atherosclerosis; Axitinib; Cell Adhesion Molecules; Cells, Cultured; Coronary Artery Disease; Disease Models, Animal; Female; Fibrillin-1; Genetic Predisposition to Disease; Hemorrhage; Human Umbilical Vein Endothelial Cells; Humans; Imidazoles; Indazoles; Mice, Knockout, ApoE; Myocardial Infarction; Neovascularization, Pathologic; Phenotype; Plaque, Atherosclerotic; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Rupture, Spontaneous; Signal Transduction; Ventricular Function, Left	2018
Quantifying the relationship between inhibition of VEGF receptor 2, drug-induced blood pressure elevation and hypertension. British journal of pharmacology, 2018, Volume: 175, Issue:4 Topics: Angiogenesis Inhibitors; Animals; Axitinib; Blood Pressure; Dose-Response Relationship, Drug; Endothelial Cells; Human Umbilical Vein Endothelial Cells; Humans; Hypertension; Imidazoles; Indazoles; Protein Kinase Inhibitors; Rats; Swine; Vascular Endothelial Growth Factor Receptor-2	2018
Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice. Endocrine, 2018, Volume: 59, Issue:2 Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Survival Rate; Thyroid Neoplasms; Treatment Outcome	2018
Development of a method to determine axitinib, lapatinib and afatinib in plasma by micellar liquid chromatography and validation by the European Medicines Agency guidelines. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2018, Feb-01, Volume: 1074-1075 Topics: Afatinib; Antineoplastic Agents; Axitinib; Chromatography, Liquid; Drug Stability; Humans; Imidazoles; Indazoles; Lapatinib; Limit of Detection; Linear Models; Micelles; Neoplasms; Quinazolines; Reproducibility of Results	2018
CCAT1 stimulation of the symmetric division of NSCLC stem cells through activation of the Wnt signalling cascade. Gene therapy, 2018, Volume: 25, Issue:1 Topics: Axitinib; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Division; Genetic Therapy; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Lung Neoplasms; MicroRNAs; Neoplastic Stem Cells; Prognosis; RNA, Long Noncoding; Wnt Signaling Pathway	2018
The FDA approved PI3K inhibitor GDC-0941 enhances in vitro the anti-neoplastic efficacy of Axitinib against c-myc-amplified high-risk medulloblastoma. Journal of cellular and molecular medicine, 2018, Volume: 22, Issue:4 Topics: Antineoplastic Agents; Axitinib; Cell Line, Tumor; Cell Survival; Clone Cells; Drug Synergism; Humans; Indazoles; Medulloblastoma; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Risk Factors; STAT3 Transcription Factor; Sulfonamides; United States; United States Food and Drug Administration	2018
The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models. Cancer immunology, immunotherapy : CII, 2018, Volume: 67, Issue:5 Topics: Animals; Antibodies, Monoclonal; Axitinib; Carcinoma, Lewis Lung; Disease Models, Animal; Drug Synergism; Hepatitis A Virus Cellular Receptor 2; Imidazoles; Immunosuppression Therapy; Immunotherapy; Indazoles; Mice; Mice, Inbred C57BL; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured; Tumor Necrosis Factor Receptor Superfamily, Member 9; Vascular Endothelial Growth Factor A	2018
Design, Synthesis, and Biological Evaluation of Axitinib Derivatives. Molecules (Basel, Switzerland), 2018, Mar-23, Volume: 23, Issue:4 Topics: Angiogenesis Inhibitors; Axitinib; Carcinoma, Renal Cell; Cell Line, Tumor; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Vascular Endothelial Growth Factor Receptor-2	2018
The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma. Journal of managed care & specialty pharmacy, 2018, Volume: 24, Issue:4 Topics: Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Cost-Benefit Analysis; Disease-Free Survival; Drug Costs; Everolimus; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Models, Economic; Nivolumab; Pyridines; Randomized Controlled Trials as Topic; Treatment Outcome	2018
[Continuation of Axitinib for Advanced Renal Cell Carcinoma by The Application of Homecare Urology - A Case Report and Literature Review]. Gan to kagaku ryoho. Cancer & chemotherapy, 2018, Volume: 45, Issue:4 Topics: Axitinib; Carcinoma, Renal Cell; Fatal Outcome; Home Care Services; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors	2018
Biomarkers defining probability of receiving second-line targeted therapy in metastatic renal cell carcinoma. Medical oncology (Northwood, London, England), 2018, May-08, Volume: 35, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Anilides; Axitinib; Biomarkers, Tumor; Brain Neoplasms; Carcinoma, Renal Cell; Everolimus; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Models, Statistical; Molecular Targeted Therapy; Protein Kinase Inhibitors; Pyridines	2018
[Synergistic anti-tumor effects of axitinib and doxorubicin]. Yao xue xue bao = Acta pharmaceutica Sinica, 2016, Volume: 51, Issue:8 Topics: A549 Cells; Animals; Antibiotics, Antineoplastic; Axitinib; Cell Cycle; Doxorubicin; Drug Synergism; Humans; Imidazoles; Indazoles; Mice; Mice, Nude; Xenograft Model Antitumor Assays	2016
Cyclooxygenase inhibitors potentiate receptor tyrosine kinase therapies in bladder cancer cells in vitro. Drug design, development and therapy, 2018, Volume: 12 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Axitinib; Benzamides; Caspases; Cell Line, Tumor; Cell Survival; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Dogs; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imidazoles; Indazoles; Indomethacin; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Pyridines; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Thiazoles; Urinary Bladder Neoplasms	2018
Aortic Dissection and Cardiac Dysfunction Emerged Coincidentally During the Long-Term Treatment with Angiogenesis Inhibitors for Metastatic Renal Cell Carcinoma. International heart journal, 2018, Sep-26, Volume: 59, Issue:5 Topics: Aged; Angiogenesis Inhibitors; Aortic Dissection; Axitinib; Carcinoma, Renal Cell; Heart Diseases; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Vascular Endothelial Growth Factor A	2018
Efficacy of Axitinib as Second-line Treatment in Locally Advanced and Metastatic Renal Cell Carcinoma. Anticancer research, 2018, Volume: 38, Issue:9 Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Chi-Square Distribution; Disease Progression; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome	2018
Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study. Clinical genitourinary cancer, 2019, Volume: 17, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Carcinoma, Renal Cell; Denosumab; Drug Therapy, Combination; Everolimus; Female; Follow-Up Studies; Humans; Hypocalcemia; Indazoles; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Prognosis; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib	2019
Phorbol esters induce PLVAP expression via VEGF and additional secreted molecules in MEK1-dependent and p38, JNK and PI3K/Akt-independent manner. Journal of cellular and molecular medicine, 2019, Volume: 23, Issue:2 Topics: Anthracenes; Autocrine Communication; Axitinib; Butadienes; Flavonoids; Gene Expression Regulation; Human Umbilical Vein Endothelial Cells; Humans; Imidazoles; Indazoles; MAP Kinase Kinase 1; MAP Kinase Kinase 4; Membrane Proteins; Nitriles; Phosphatidylinositol 3-Kinases; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Pyrimidines; RNA, Small Interfering; Signal Transduction; Sulfonamides; Tetradecanoylphorbol Acetate; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2019
Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. European journal of cancer (Oxford, England : 1990), 2019, Volume: 108 Topics: Adult; Aged; Anilides; Antineoplastic Agents, Immunological; Axitinib; Carcinoma, Renal Cell; Female; Humans; Indazoles; Ipilimumab; Kidney Neoplasms; Male; Middle Aged; Nivolumab; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Sunitinib; Treatment Failure	2019
Checkpoint Inhibitor-TKI Combos Effective in RCC. Cancer discovery, 2019, Volume: 9, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Sunitinib	2019
[Axitinib in real life, analysis of our results.] Archivos espanoles de urologia, 2019, Volume: 72, Issue:4 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Retrospective Studies; Treatment Outcome	2019
Folic Acid Reduces Mucositis in Metastatic Renal Cell Carcinoma Patients: A Retrospective Study. Clinical genitourinary cancer, 2019, Volume: 17, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Everolimus; Female; Folic Acid; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Mucositis; Neoplasm Metastasis; Pyrimidines; Retrospective Studies; Sirolimus; Sulfonamides; Sunitinib; Treatment Outcome	2019
Bone metastasis is associated with poor prognosis in metastatic papillary renal cell carcinoma patients treated with first agent angiogenesis inhibitors. Urologic oncology, 2020, Volume: 38, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Bone Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Prognosis; Pyrimidines; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome	2020
Comprehensive analysis of copy number variance and sensitivity to common targeted therapy in clear cell renal cell carcinoma: In silico analysis with in vitro validation. Cancer medicine, 2020, Volume: 9, Issue:16 Topics: Anilides; Antineoplastic Agents; Arylsulfotransferase; Axitinib; Carcinoma, Renal Cell; Carrier Proteins; Cell Line, Tumor; Chromogranins; Computer Simulation; Cyclin E; DNA Copy Number Variations; Drug Resistance, Neoplasm; GTP-Binding Protein alpha Subunits, Gs; Humans; Indazoles; Kidney Neoplasms; Oncogene Proteins; Pituitary Adenylate Cyclase-Activating Polypeptide; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Sirolimus; Sulfonamides; Sunitinib	2020
Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK. BMC cancer, 2020, Jul-17, Volume: 20, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Everolimus; Female; Follow-Up Studies; Humans; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Longitudinal Studies; Male; Middle Aged; Molecular Targeted Therapy; Practice Patterns, Physicians'; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome; United Kingdom; Young Adult	2020
Treating metastatic clear-cell renal cell carcinoma: beyond immunotherapy. Medical oncology (Northwood, London, England), 2020, Aug-07, Volume: 37, Issue:9 Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Immunotherapy; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Metastasis; Nivolumab; Patient Selection; Phenylurea Compounds; Pyridines; Pyrimidines; Quinolines; Sulfonamides; Sunitinib	2020
Activation of inflammasomes by tyrosine kinase inhibitors of vascular endothelial growth factor receptor: Implications for VEGFR TKIs-induced immune related adverse events. Toxicology in vitro : an international journal published in association with BIBRA, 2021, Volume: 71 Topics: Antineoplastic Agents; Axitinib; Caspases; HMGB1 Protein; Humans; Indazoles; Indoles; Inflammasomes; Interleukin-1beta; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; THP-1 Cells	2021
Efficacy and safety of second-line axitinib in octogenarians with metastatic renal cell carcinoma. Journal of geriatric oncology, 2021, Volume: 12, Issue:5 Topics: Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Treatment Outcome	2021
Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. Cancer medicine, 2021, Volume: 10, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anilides; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Female; Humans; Immune Checkpoint Inhibitors; Indazoles; Ipilimumab; Kidney Neoplasms; Male; Middle Aged; Nivolumab; Phenylurea Compounds; Programmed Cell Death 1 Receptor; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinolines; Retrospective Studies; Sulfonamides; Survival Rate; Treatment Outcome	2021
Efficacy of axitinib rechallenge in metastatic renal cell carcinoma. International journal of urology : official journal of the Japanese Urological Association, 2021, Volume: 28, Issue:6 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Protein Kinase Inhibitors; Treatment Outcome	2021
Real-World Study Evaluating Safety and Effectiveness of Axitinib in Korean Patients with Renal Cell Carcinoma after Failure of One Prior Systemic Therapy. Cancer research and treatment, 2023, Volume: 55, Issue:2 Topics: Aged; Axitinib; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Male; Republic of Korea; Treatment Outcome	2023
Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairment. Urologic oncology, 2023, Volume: 41, Issue:11 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Cohort Studies; Humans; Indazoles; Kidney Neoplasms; Treatment Outcome	2023